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Cardiac fibroblasts play a major role in fibrogenesis associated with heart failure, since 
they produce ECM components and secrete important fibrosis-associated mediators, 
such as connective tissue growth factor (CTGF). CTGF expression and secretion can be 
induced by the angiotensin II (Ang II) type1 receptor (AT1-R) activation. Within this 
thesis, the role of the Ca2+- and cytoskeleton-dependent signaling pathways elicited by 
Ang II on the regulation of CTGF were investigated in neonatal rat cardiac fibroblasts 
(NRCF). Ang II was shown to induce a Ca2+ transient via the PLC-β canonical pathway 
with an EC50 in a physiological range. This transient was detectable in the absence of 
extracellular Ca2+ and in accordance, the depletion of intracellular Ca2+ by thapsigargin 
(TGN) completely suppressed it. Interestingly, the blockade of the transmembrane 
TRPC3 channels by pyrazole 3 increased this transient and strongly inhibited the Ang II-
induced Ca2+ oscillations. In addition, the Ca2+ oscillation could be also blocked by TGN. 
Moreover, the NADPH oxidase and its accessory activator Rac1 were found to be 
involved in the regulation of the induced Ca2+ transient in the cytosol and in 
mitochondria. In the next step, the impact of Ca2+ and its effector proteins were studied 
on CTGF expression and secretion. First, to demonstrate the overall outcome of Ca2+ on 
the regulation of CTGF, BAPTA-AM was used and showed that the chelation of 
intracellular Ca2+ resulted in the inhibition of CTGF expression and secretion. Second, 
with help of the inhibitor Go 6983 the involvement of protein kinase C (PKC) as a 
downstream mediator could be established. Third, in contrast to the downregulation of 
CTGF expression by PKC inhibition, an increase in CTGF expression was found in 
response to calcineurin inhibition by cyclosporin A (CsA). Next, the role of the actin 
cytoskeleton and of microtubules were studied. Actin filament disruption by latrunculin A 
(LAT-A) led to a similar decrease in CTGF expression as BAPTA-AM, which also had an 
actin depolymerizing effect. Similar, PKC inhibition was found to disrupt the actin 
cytoskeleton. All three interventions led in addition to major morphological changes of 
the Golgi apparatus, which is the major storage place of CTGF. In contrast to the actin 
cytoskeleton, the integrity of the microtubules was not affected under most conditions. 
To finally determine the role of these thick filaments in CTGF regulation, the 
microtubules depolymerizing drug colchicine was applied, which dispersed the Golgi 
apparatus, increased the CTGF expression and uncoupled it from the AT1R signaling 
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cascade. In summary, CTGF is regulated by a crosstalk of Ca2+-dependent signaling, 
involving PKC and calcineurin, and cytoskeleton-dependent pathways involving actin 





Heart diseases are the most common death causes not only in industrial societies, but 
also in low- and middle-income countries. During the last decades, huge efforts have 
been made to understand the molecular mechanisms involved in the dysregulation of 
cardiac function in order to improve the pharmacological therapy. Despite the 
intervention with several classes of modern therapeutics has clearly reduced the 
mortality of cardiac diseases, it is still not possible to reverse the diseased cardiac 
phenotype, this is most likely due to our limited knowledge of the detailed underlying 
molecular pathomechanisms. One reason for this might be attributed to the strong 
research focus on the malfunction of cardiomyocytes, disregarding the complex cellular 
composition of the cardiac tissue, where non-cardiomyocytes compose a major cell 
population [1]. It can be assumed that these cells, including cardiac fibroblasts, 
endothelial cells, pericytes, smooth muscle cells and immune cells, communicate with 
each other as well as with the cardiomyocytes and are therefore similarly affected by the 
neurohumoral changes occurring in heart diseases [2, 3]. Moreover, it is highly possible 
that non-cardiomyocytes expedite the progression of the cardiac remodelling as 
occurring in heart diseases [4].  
 
 
2.1. Heart failure 
 
Heart failure (HF) is a common cause for disability and death worldwide. According to a 
global epidemiological study in the year 2012, the prevalence of HF was over 23 million 
worldwide, with a lifetime risk of developing the disease to be one in five, and a five-year 
mortality rate that is higher than in many types of cancer [5]. 
 
HF is a progressive chronic disease that is generally characterized by imbalance 
between cardiac output and the metabolic demand of the body. It usually results from 
diminished contractility of the myocardium (systolic dysfunction), inadequate filling of the 
3 
 
heart (diastolic dysfunction), or more often a combination of both dysfunctions. Several 
underlying disease conditions have long been identified to stand behind cardiac 
dysfunctions, including myocardial infarctions (MI), chronic ischemia, dilated 
cardiomyopathy, ventricular hypertrophy (which results from chronic pressure overload 
or volume overload), cardiac valves stenosis and pericardial diseases. Any of these 
diseases can weaken cardiac contractility and so can reduce cardiac output, leading to a 
reduction in renal blood perfusion, which in turn activates the renin-angiotensin II (Ang 
II)-aldosterone system (RAAS), resulting in increased Ang II generation and aldosterone 
secretion, which mediate several events that are associated with cardiac remodeling, 
such as hypertrophy and fibrosis. On the other hand, the reduction in the cardiac output 
results in the activation of the sympathetic nervous system, due to a decline in carotid 
sinus firing. The persistent activation of the sympathetic nervous system on one side 
contributes to the myocardial remodeling, and on the other side causes desensitization 
of the β-adrenergic receptors. Together, cardiac remodeling and β-adrenergic receptors 
desensitization further exacerbate the dysfunction of cardiac contractility and cardiac 
output, and by that a vicious cycle is initiated, which persists along the progression of the 
disease (Fig. 1) [6]. It is worthy to mention that in the early stage of HF development, the 
activation of the RAAS as well as the sympathetic activation improve cardiac function, 
but the chronic activation of these two systems leads to the detrimental, irreversible and 






Figure 1: Vicious circle of heart failure 
The reduction of the cardiac output, due to several underlying etiologies, induces the 
activation of the sympathetic nervous system and RAAS, which eventually results in the 
desensitization of the β-adrenergic receptors and in cardiac remodeling, and 




2.2. Cardiac fibrosis 
 
Cardiac fibrosis is a feature of cardiac remodeling that occurs along the course of HF 
development. It is characterized by increased deposition of extracellular matrix (ECM) 
proteins, mainly by activated cardiac fibroblasts (CF) as well as by vascular smooth 
muscle cells [9]. There are two types of fibrosis: reparative fibrosis, which is secondary 
to cardiac cell necrosis as in the case of ischemia and aging, where the dead tissue is 
replaced by a scar. The second type of fibrosis is the reactive fibrosis, which results from 
persistent stimulation of CF, but without direct tissue injury as in the case of chronic 
hypertension [10]. With time, reactive fibrosis causes necrosis and apoptosis of 
cardiomyocytes, resulting in reparative fibrosis. Cardiac fibrosis increases the stiffness of 
the myocardium, thus impairs cardiac filling and contraction of the myocardium [9]. 
  
 
2.3. Contribution of CF to cardiac remodeling 
 
2.3.1. CF and myocardium homeostasis 
 
The CF numerically comprise a major cell population of the myocardium [11]. Normally 
they produce and deposit ECM proteins, including collagen types I, III, V and VI, laminin, 
elastin, proteoglycans and glycosaminoglycan. In the same time they secret different kinds 
of matrix metalloproteinases (MMPs) which degrade ECM as well as tissue inhibitors of 
metalloproteinases (TIMPs) [12]. Under healthy conditions, the balance between synthesis 
and turnover of ECM by CF is tightly regulated, so that CF can build up a 3D network of 
connective tissue, where myocytes, fibroblasts and ECM interact with each other in a way 
that ensures structural integrity of the heart, proper distribution of contraction force and 
proper electromechanical function of the myocardium [4]. In vitro studies have shown that 
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CF can couple to cardiomyocytes via connexin 43, and that this coupling allows 
synchronization of spontaneous beating of distant cardiomyocytes, which suggests a 
potential role in the regulation of electrophysiology of the heart [13]. In addition, the 
connective tissue that is synthesized by CF acts as a natural electrical insulator, which 
allows gradual distribution of electrical impulse throughout the cardiac tissue being 
important for the orderly contraction of the different parts of the heart [14]. Moreover, CF 
secret a plethora of bioactive molecules, such as connective tissue growth factor (CTGF), 
transforming growth factor-beta (TGF-β), tumor necrosis factor-alpha (TNF-α), interleukin 
1beta (IL-1β), interleukin-6 (IL-6), endothelin-1 (ET), natriuretic peptides and vascular 
endothelial growth factor (VEGF). These mediators generally function in an autocrine and 
paracrine fashion to regulate proliferation, migration, differentiation, gene expression and 
secretion of mediators by CF and other cells. Interestingly, it was also found that CF can 
secrete all components of the RAAS system including angiotensinogen, renin and the 
angiotensin converting enzyme (ACE), which allows local generation of Ang II in the 
microenvironment of CF and cardiomyocytes. This might play a central role in myocardial 




2.3.2.  Differentiation of CF into myofibroblasts 
 
Under stress conditions, like cardiac injury and chronic hypertension, CF tend to 
differentiate into myofibroblasts (MyoF), which are disease-affected CF [16] and normally 
not present in a healthy myocardium [4]. MyoF acquire the ability to express α-smooth 
muscle-actin (sm-actin), allowing the contraction of ECM fibers, they also acquire greater 
capacity to secret bioactive molecules, ECM proteins, MMPs and TIMPs, which help MyoF 
in scar formation (Fig. 2) [15, 17, 18]. Usually after successful wound closure the MyoF 
e.g. in the skin undergo apoptosis [19], but the scenario that occurs in the infarct heart is 
somewhat different. For so far unclear reasons, following “healing” and scar formation, 
MyoF in the mature infarct scar persist for a long time, months or years [20], and play a 
key role in excessive scaring and fibrosis. Eventually, they participate in the pathogenesis 







Figure 2: Role of CF in cardiac remodeling 
The different biological activities of CF are essential for the maintenance of the 
myocardium homeostasis. Under stress conditions, CF differentiate into MyoF, which 
have enhanced biological activities that are in favor of supporting myocytes hypertrophy 
and the increased deposition and turnover of the ECM, which contributes to the 
myocardium remodeling.  
 
 
Experimentally it is difficult to analyze the distinct functions of CF and MyoF, as 
maintaining the CF phenotype in culture is challenging. Whenever these cells are seeded 
on plastic cell culture plates/dishes, they spontaneously start to differentiate into MyoF, 
which can be detected by an increased expression of α-sma. In this case, CF differentiate 
into MyoF because plastic surfaces are generally stiffer than healthy cardiac tissue [22]. 
Therefore, most of the current publications about fibroblasts are actually showing data on 
7 
 
the pathobiology of MyoF, and consequently there is a lack of information on precise 
differences between CF and MyoF. In addition, the more these cells are passaged, the 
more they express α-sma, i.e. the more they acquire the myofibroblastic phenotype [16]. 
Several other factors have been indentified so far which shift CF characteristics into more 
myofibroblastic phenotype including the presence of serum, glucose level in the culture 
medium, the addition of certain bioactive molecules like TGF-β and the electrical and 
mechanical stimulation [23-26].  
 
 
2.4. Role of Ang II in the pathogenesis of cardiac fibrosis 
 
In patients with HF, the levels of Ang II in the circulation, myocardium and the central 
nervous system are increased [27, 28]. Beside the fact that Ang II induces hypertrophy 
in cardiomyocytes [29], Ang II also induces the differentiation of CF into MyoF [30], and it 
stimulates these cells to deposit ECM proteins [31] and to secret profibrotic mediators 
such as TGF-β and CTGF [32, 33].  
 
Ang II is the active end product of the RAAS, where angiotensinogen is converted by 
renin into angiotensin I, which is then cleaved by the angiotensin converting enzyme 
(ACE) into Ang II. Two isotypes of Ang II receptors have been identified both belong to 
the G-protein coupled receptor (GPCR) superfamily and are named as AT1 and AT2 
receptors. In healthy adult individuals, Ang II exerts its biological functions mainly via 
activation of the AT1 receptors [34]. In the adult heart, AT1 receptors are expressed in 
different cardiac cell types including CF [35], cardiomyocytes [36] and vascular smooth 
muscle cells [37]. They are able to couple to different isoforms of G-proteins at the same 
time, and therefore, they can simultaneously initiate different signal transduction 
pathways depending on the activated G-protein. Each of the activated G-proteins can in 
turn activate several signaling cascades, which crosstalk with each other and regulate 
each other. Therefore, the activation of AT1 receptors initiates a highly complex 








2.4.1. Ang II-induced reactive oxygen species production in CF 
 
In general, reactive oxygen species (ROS) are highly reactive oxygen derivatives, such 
as hydrogen peroxide (H2O2) and superoxide (O2
.-), which have a great capacity to 
interact with and oxidize various cellular macromolecules resulting in modifications that 
influence the functionality and activity of the affected molecules. The role of ROS in the 
physiology of immune cells was identified as early as in the1960s, when it was found 
that ROS generation is crucial for the elimination of phagocytized pathogens by immune 
cells [38, 39]. Later ROS generation was detected in various non-immune tissues, which 
was perceived as an unfavourable and inevitable event that accompanies the normal 
catalytic activities of enzymes, which can participate under certain circumstances in the 
pathogenesis of several diseases including heart failure [40, 41]. However, the intensive 
investigations for the biology of ROS over the last few decades expanded our 
understanding of ROS biology to include, beside pathological effects, vital contributions 
to cellular physiology [42]. 
 
The generation of ROS is usually performed by the multi-subunit NADPH oxidases 
(NOXs), which are localized to various subcellular microdomains such as caveolae, 
mitochondria, the nucleus, and endosomes, and therefore the generation of ROS is 
thought to be highly compartmentalized, which allows specific targeting of certain 
signaling cascade molecules [43, 44]. The NOX family consists of several isozymes: 
NOX1-5 and 2 related enzymes (DUOX1, DUOX2). These enzymes catalyze the 
transfer of one electron from NADH or NADPH to an oxygen molecule (O2) converting it 
into superoxide (O2
.-), which can be converted into H2O2 by superoxide dismutase [45]. 
NOXs are generally known to be differentially expressed in different cardiac cell types. In 
CF several publications have shown that NOX2 and NOX4 are expressed, but the 
expression of other NOXs cannot be excluded. NOX2 is composed of two membrane-
spanning subunits, which are an oxidizing subunit (gp91phox also called NOX2) and a 
complex stabilizing subunit (p22phox), besides the three cytoplasmic components 
Rac1/2, p40phox, p67phox and p47-phox. Likewise, NOX4 also has two membrane-
spanning subunits; the complex stabilizing p22phox subunit and the oxidizing NOX4 
subunit. The involvement of cytoplasmic subunits in NOX4 activation is still unclear; 
some publications reported an association with Poldip2 [46], others suggested a Rac1-
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mediated activation [47], and some suggested that NOX4 is constitutively active and 
does not require additional regulatory subunits [48-50]. 
 
ROS has been also shown to be involved in the fibrogenesis of several organs including 
heart, lung, liver and kidney [51]. In the heart, ROS generation is acutely upregulated in 
response to ischemia/reperfusion of the myocardium that occurs during MI [52], and is 
also chronically generated in the myocardium of patients with heart failure in response to 
chronic Ang II and TGF-β stimulation [53]. Ang II-induced NOX activation in CF has been 
shown to mediate several fibrogenic effects such as the induction of fibroblasts 
proliferation and differentiation into MyoF, the deposition and organization ECM proteins 
[51, 54], the epithelial-mesenchymal transformation [55], as well as the induction of 
several pro-fibrotic genes including endothelin-1 [56], TGF-β [57], MMPs [58] and CTGF 
[59]. 
 
It has been reported that among the different signaling pathways initiated by AT1 
receptors, only G-proteins are important for NOX activation. Gαq and Gβγ subunits 
activates PLC-β, which mediates the increase in cytosolic Ca2+ concentration along with 
the generation of DAG, both of which work together to activate protein kinase C (PKC), 
which in turn phosphorylates p47phox, causing the translocation of the p47phox-
p67phox complex from the cytosol to the Nox2-p22phox trans-membrane complex. In 
the same time, Gβγ subunit activates phosphatidylinositol 3-kinase (PI3K), which 
activates Rac1 protein causing it to translocate from the cytosol to join the Nox2-
p22phox trans-membrane complex. By that, NOX2 complex is complete and is able to 
produce ROS. On the other hand, PKC causes by unknown mechanism the association 
of NOXA1 and NOXO1 to the NOX1-p22phox trans-membrane complex. Also activated 
Rac1 associates with NOX1 complex and contributes to its activity. Phospholipase D2 
(PLD2) is activated by DAG and is thought to be important to replenish the precursors of 






Figure 3: Mechanism of NOX1/2 activation by Ang II 
Ang II can induce the assembly of the subunits of NOX1/2 via PLC-β-PKC signaling 
pathway, which is activated by Gαq and Gβγ subunits of G-protein. In the same time, 
Gβγ subunit mediates PI3K-depndent activation of Rac1, a necessary step to allow the 
association of Rac1 with NOX1/2 complexes. The scheme was adopted from Choi and 
coworkers [60].     
 
 
Moreover, it has been shown that when the AT1 receptors are activated, they 
translocate to cholesterol rich rafts in the cell membranes called caveolae, which are 
associated with caveolin-1 and hold several signaling molecules, including NOXs [61-
63]. Interestingly, Ang II-induced Rac1 activation and ROS generation can be inhibited 
when the integrity of the caveolae was disrupted [63, 64]. In addition, Ang II was found to 
induce the expression of p67phox and p22phox subunits in adventitial and CF [65, 66]. 
Another Ang II-dependent signaling pathway for the activation of NOX has been reported 
in CF through the activation of Gα12/13 and Rac1, which was shown to be important for 






2.4.2. Regulation of TGF-β by Ang II signaling 
 
TGF-β is elevated in the circulation and myocardium of patients with HF [68] and in the 
myocardium of patients with MI [69]. Also it has been shown that cultured human CF and 
neonatal rat CF can secret this cytokine. TGF-β induces the differentiation of CF into 
MyoF, an action that is thought to be mediated by the generation of ROS [70, 71], and it 
stimulates these cells to deposit ECM proteins [25, 32] and to secret the profibrotic 
CTGF protein [72]. Different stimuli can upregulate TGF-β, such as Ang II and ROS 
generation [15]. It has been shown that Ang II can induce TGF-β expression via a NOX-
dependent signaling pathway, which involves PKC-dependent p38-mitogen activated 
protein (MAP) kinase activation that in turn activates the transcription factor AP-1, a step 
that is necessary for the induction of TGF-β gene transcription [73, 74]. Other proposed 
Ang II-mediated signaling pathways for the induction of TGF-β could involve the Ang II-
induced expression of Egr-1 and c-Fos transcription factors [75], which were shown to 
induce TGF-β gene transcription [76, 77].  
 
2.5. Regulation of calcium in CF 
 
2.5.1.  Ang II-dependent calcium (Ca2+) signaling 
 
AT1 receptors couple besides others (see section 1.4.1) to Gαq/11 proteins, through 
which they can activate phospholipase C-β (PLC-β) resulting in the release of 
intracellular Ca2+ from the endoplasmic reticulum (ER). This action is mediated via 
generation of the second messenger inositol triphosphate (IP3) from phosphatidylinositol 
4,5-bisphosphate (PIP2) by the PLC-β. Once IP3 is generated, it is released in the 
cytosol, where it activates the IP3 receptors (IP3R) that are located in the membranes of 
the ER. The IP3R are Ca2+ channels, which open due to the allosteric changes that 
occur in response to IP3 binding resulting in a release of Ca2+ from the ER [78-80]. This 
pathway was shown in several publications to be involved in Ang II-induced contraction 
of vascular smooth muscle cells and in cardiomyocytes [81, 82]. Besides IP3, the 
hydrolysis of PIP2 generates diacylglycerol (DAG), which remains anchored to the cell 
membrane. The Ca2+ which is released by IP3 causes the translocation of protein kinase 
C (PKC) isozymes to the plasma membrane, where they get activated by DAG [79, 83] 
and hence initiate signaling cascades which is involved in regulation of the expression of 
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several genes [84, 85]. Besides, DAG is known to activate the transient receptor 
potential canonical (TRPC) channels, which are Ca2+ permeable cation channels [86, 
87].  
 
The targets of Ca2+, which are located in the cytosol and different cellular organelles, 
sense the change in the intracellular Ca2+ concentration either directly by interacting with 
Ca2+ ions or indirectly via scaffolding proteins like calmodulin, which when activated can 
interact with different Ca2+-dependent enzymes, such as kinases and phosphatases [88], 
through which different physiological functions of Ca2+, such as the regulation of gene 
expression and vesicular secretion, can be mediated. 
 
2.5.1.1.1. PKC signaling 
 
PKC constitute an extended family of several isozymes of serine/threonine kinases that 
are known to be activated by phospholipase associated receptors. They vary mainly 
based on the composition of the regulatory domain at the N-terminus, PKC isozymes 
can be classified into three categories with various sensitivities to Ca2+ and DAG. 
Conventional PKC isozymes, such as PKCα, βI, βII, γ, require both Ca2+ and DAG for 
activation. Novel PKC isozymes, such as PKCδ, ε, η, θ, require only DAG. Atypical PKC 
isozymes, such as PKCζ, ι, μ, ν, and these isozymes are completely insensitive to Ca2+ 
or DAG [89-92].  
 
PKCα, βI, βII, δ, ε, and ζ are expressed in adult and neonatal CF [93]. Several studies 
have identified PKC as potential therapeutic targets for cardiac fibrosis associated with 
heart failure. The inhibition of PKCα and β was shown to suppress cardiac fibrosis in a 
rat post-myocardial infarction model [94]. In addition, the selective over-expression of 
PKCβII in the myocardium resulted in severe cardiac fibrosis [95]. On the other hand, the 
knockout of PKCε enhanced the interstitial cardiac fibrosis in a mouse model of pressure 
overload [96]. 
  
It has been reported that PKCε mediate the Ang II-induced adhesion of fibroblasts to the 
ECM via a mechanism involving βI-integrins. In addition, it has been found that PKCδ 
and PKCζ oppositely regulate TGF-βI-induced proliferation of neonatal rat CF [93, 97]. 
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Moreover, PKCs were found to be involved in the regulation of Ang II-induced CTGF 
expression in an isozyme-dependent manner. The blockade of PKCα, ζ, or ε inhibited 
the Ang II-induced CTGF expression, whereas the knockdown of PKCδ significantly 
enhanced the Ang II-induced CTGF expression [98].  
 
2.5.1.1.2. Calcineurin signaling 
 
Calcineurin is a Ca2+ and calmodulin-dependent protein phosphatase IIB. It is composed 
of two subunits, calcineurin A, which is the catalytic subunit, and calcineurin B, which is 
the regulatory subunit [99]. Under resting conditions, calcineurin is inactive due to the 
low cytoplasmic Ca2+ concentration, but upon the activation of the GPCR-PLC-β/γ-IP3 
pathway, the cytoplasmic Ca2+ concentration is elevated, so that Ca2+ binds calmodulin 
causing conformational changes that allow binding to calcineurin to activate its 
phosphatase activity. Ca2+ can also directly interact with the regulatory subunit of 
calcineurin [100]. The classical targets for activated calcineurin are the members of the 
nuclear factor of activated T cells (NFAT), which are transcription factors localized 
mainly to the cytosol when they are in the inactive phosphorylated state. Active 
calcineurin is necessary to dephosphorylate NFAT proteins, a step that is indispensable 
to allow NFAT proteins to cross the nuclear envelope, so that they can function as 
transcription factors [101].  
 
Calcineurin-NFAT signaling is known to be vital for normal homeostasis as well as in the 
pathogenesis of different diseases, including cardiovascular diseases [102]. Over-
expression of calcineurin was reported to induce cardiac hypertrophy and heart failure, 
which could be prevented by inhibiting calcineurin by cyclosporin A (CsA) [103]. 
Moreover, it was reported that calcineurin mediates the Ang II-induced cardiomyocytes 
hypertrophy and CF hyperplasia [104]. 
 
2.5.1.1.3. Transient receptor potential channels  
 
Transient receptor potential (TRP) channels form a superfamily of 6 related subfamilies: 
TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPA (ankyrin), TRPP 
(polycystin) and TRPML (mucolipin). All TRP channels are composed of 6-
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transmembrane domains that are arranged to form cation-permeable pores. Generally, 
these channels are nonselective cation channels with most of them showing a Ca2+ to 
Na+ permeation ratio of less than 1:10 [105-107].  
 
The TRPC channel subfamily consists of seven isoforms, numbered from 1-7. Several 
studies provided evidences that these channels can contribute to store-operated Ca2+ 
entry (SOCE) [108, 109], nevertheless, it is still controversial whether they are instead a 
specialized receptor-operated Ca2+ entry (ROCE) mediators, that replenish the 
intracellular Ca2+ stores following IP3-mediated Ca2+ release, as in the case of 
TRPC3/6/7 [86, 107]. Some TRPC channels have been reported to act as 
mechanosensitive channels [110, 111]. However, the mechanism of TRPC channel 
activation is still highly unclear, and the data available show lots of controversial findings, 
since so many factors are involved in the regulation of the activity of these channels, 
including the cell type, the level of expression, the cellular localization and the availability 
of interaction partners [107].    
      
Several isoforms of TRPC channels, such as TRPC1/3/5/6 were shown to be 
upregulated and involved in the pathogenesis of heart failure in several animal models, 
where calcineurin-NFAT signaling was frequently involved, which mediates the 
expression of several hypertrophic genes. Moreover, TRPC1/3 were found to be 
upregulated in cardiomyocytes in response to Ang II, endothelin-1 and phenylephrine 
treatment [112-116].  
 
 
2.5.2. Ca2+ oscillation in CF 
 
Ca2+ oscillation is a repetitive cyclical change in the cytoplasmic Ca2+ concentration 
observed in different types of cells, especially the non-excitable ones, in response to 
different physiological stimuli. There are evidences that the amplitude, frequency and 
duration of these signals actually play a major role in the regulation of different cellular 
processes such as, proliferation, contraction and secretion [117-119].  
 
It has been shown that GPCR activation results in cyclic generation of IP3 that was 
consistently parallel with the cyclic change in the cytoplasmic Ca2+ levels [120-122]. In 
the same time, Bird and Putney, 2005 reported that the intracellular Ca2+ stores are the 
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major source of the oscillating Ca2+ supported by an Ca2+ influx through store-operated 
Ca2+ channels (SOC), such as Orai1 channels [117]. During Ca2+ oscillation the 
reduction of the Ca2+ concentration in the endoplasmic reticulum,  is sensed by the 
stromal interaction molecule 1 (STIM1), which in turn causes the plasma membrane 
Orai1 channels to open: This mechanism is important to maintain the filling of the 
endoplasmic Ca2+ stores [123]. Moreover, it was reported that TRPC3 channels can 
mediate agonist-activated Ca2+ oscillation via non-capacitative calcium entry [117, 124], 
besides several other publications that reported direct and indirect coupling between the 
IP3Rs and the TRPC3 channels [125-127]. Therefore, it can be hypothesized that 
TRPC3 channels play a role in Ca2+ oscillation via regulating the activity of the IP3Rs. 
Recent studies in MyoF have reported a correlation between the frequency of Ca2+ 
oscillation and the cycles of MyoF contractions, which was dependent on the elastic 
modulus of the cell culture surface as well as on the intracellular mechanical stress that 
is transduced by actin filaments [128]. Ca2+ oscillation was found to be synchronized 
between physically contacting MyoF, which is mediated by adherens junctions, 
suggesting that the mechanosensitive ion channels could be involved [129]. 
 
2.6. Regulation of bioactive molecules expression and secretion 
 
Several studies have shown that actin filaments and microtubules function is not limited 
to the provision of physical support to the cells, but rather extend to include the 
regulation of various cellular processes, such as the regulation of gene expression and 
vesicular secretion. Actin filaments and microtubules were reported to function as tracks 
along which the secretory vesicles travel towards the cell membrane. In addition, they 
can regulate the kinetics of some transcription factors, and also transduce physical 
signals from the outer environment to the nucleus, whereby they can regulate the 
expression of different genes [130]. 
 
2.6.1. Regulation of secretory processes by Ca2+  
 
The role of Ca2+ in the mechanism of neurotransmitters and hormones secretion has 
been recognized and well characterized over the last few decades. The release of the 
neurotransmitters is normally triggered in response to the influx of Ca2+ through voltage-
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gated Ca2+ channels, which are activated by action potentials. Whereas, the secretion of 
hormones is usually triggered by intracellular Ca2+ release that is mediated by GPCR-
PLC-β-IP3 signaling pathway. Ca2+ is known to be involved in the mechanism of 
intracellular secretory vesicle trafficking [131] and fusion of the secretory vesicles with 
the target cell membrane, which involves interaction with the Ca2+ sensor 
synaptotagmin-1 protein [132]. Synaptotagmin is located on the membrane of the 
secretory vesicles and has two C2 domains (C2A and C2B) that are homologous to the 
Ca2+-binding domain of PKC. The C2A domain binds syntaxin SNAP-25 proteins (the 
cell membrane components of the SNARE complex) and phospholipids on the cell 
membrane in a Ca2+ dependent manner, which is important to tether the secretory 
vesicles to the plasma membrane and facilitate membrane fusion and exocytosis [133]. 
 
2.6.2. Regulation of gene expression by actin filaments and microtubules 
 
Actin filaments, also called microfilaments, are polymers of globular actin (G-actin) that 
forms flexible double-stranded helix fibers of several micrometers in length and up to 7 
nm in diameter. They form higher order structures of bundles and networks. Actin 
polymerization is a reversible spontaneous process that can be facilitated by the 
hydrolysis of the ATP bound to G-actin to ADP. The rate of actin polymerization is 
proportional to the concentration of the G-actin, and normally there is equilibrium 
between actin polymerization and dissociation. Several actin-binding proteins regulate 
the assembly and disassembly of the actin filaments, such as cofilin that enhances the 
rate of actin filaments depolymerization, profilin that antagonizes the function of cofilin by 
enhancing the exchange of ADP for ATP on G-actin, and the actin related proteins 
(Arp2/3) proteins, which functions as a nucleation point for the polymerization of a new 
actin filaments [134, 135]. RhoA GTPase is also a major promoter for actin filaments 
polymerization. It functions mainly via two downstream signaling pathways: one that is 
mediated through the Rho-kinases (ROCK) that activate LIM kinase-mediated 
phosphorylation of cofilin, which inactivates cofilin, resulting in the stabilization of the 
actin filaments [136]. The other pathway involves the activation of the formins (mDia1 





Several extracellular stimuli, such as GPCRs (coupled to Gαq/11 and Gα12/13), TGF-β 
receptors and integrins, can modulate the activity of the RhoGTPases through Rho 
guanine nucleotide exchange factors (GEFs), which influences the rate of actin filaments 
organization, and thereby the concentration of cytoplasmic free G-actin. High 
cytoplasmic free G-actin is known to bind myocardin-related transcription factors 
(MRTFs), preventing them from entering the nucleus and therefore interacting with the 
serum response factor (SRF), as a result SRF cannot induce gene expression. 
Therefore, the equilibrium between the polymerized and free actin can regulate the 
expression of certain gene expression [138].  
 
Microtubules are composed of a polymer of α-tubulin and β-tubulin monomers that are 
alternatively linked together to form protofilaments, each 13 protofilaments associate 
laterally to form a hollow cylindrical polymer of 25 nm in diameter. γ-tubulin are specially 
located in the microtubule organizing centers, from which the microtubules 
polymerization originates, so that the α-tubulin subunit is exposed at the beginning of the 
protofilament (-) end and the β-tubulin subunit exposed at the opposite end (+) end, at 
which the elongation of the microtubule usually occurs [139]. Microtubules need GTP for 
polymerization and stability, and the status of the microtubules oscillate between regular 
growing phase and rapid disassembly phase (catastrophe). The loss of the GTP-bound 
tubulin from the (+) end of growing protofilaments is believed to result in the instability of 
the microtubule protofilaments, causing them to shift to the catastrophe phase [140]. 
  
The disruption of microtubules has been shown by different studies to change the 
expression of different genes. It has been shown by Cho and coworkers that treatment 
with Nocadazole, an effective microtubules disrupting drug, was associated with the 
modulation of gene expression of 50 genes [141]. Moreover, it was shown that 
microtubules sequester Smad2 transcription factors, making them less available to 
activation by TGF-β receptors [142]. Several other transcription factors, such as MIZ-1 
and Egr3 were found to associate with the microtubules, so that their activity was 





2.7. Connective tissue growth factor  
 
The connective tissue growth factor (CTGF), also known as CCN2, was first identified as a 
platelet derived growth factor (PDGF)-related mitogen that is secreted by human vascular 
endothelial cells [145-147]. Later, it was shown that CTGF is highly expressed during 
embryonic development and re-expressed in almost all fibrotic tissues including the fibrotic 
heart. With this respect, it has been demonstrated that MyoF but also other cardiac cells 
are substantial sources of CTGF.  
 
 
2.7.1. Protein structure of CTGF 
 
The analysis of its protein structure revealed that it is a 38-kDa cysteine-rich protein that 
is composed of four modules: I) insulin-like growth factor binding protein module 
(IGFBP) for the binding of insulin-like growth factor (IGF), II) von Willebrand factor type 
C (VWF-C) module for the binding of TGF-β and bone morphogenetic proteins-4 (BMP-
4), III) thrombospondin (TSP)-type I homology module for the binding of vascular 
endothelial growth factors (VEGF) and various isoforms of integrins and some cell 
surface receptors like LRP-1. This module has a cysteine-rich (CR) region. And finally, 
IV) the carboxy-terminal (CT) cysteine knot motif and heparin-binding module for the 
binding of proteoheparan sulphate proteoglycans, which allows the binding and 
interaction with the ECM proteins. This complex structure combining growth factor 






Figure 4: Protein structure of CTGF 
The scheme shows the 4 modules of CTGF and their interactions with different growth 
factors, cell surface and ECM proteins. It also shows the cleavage sites for proteases 
and plasmin. The scheme was adapted with modifications from de Winter and coworkers 
and Gressner and Gressner [145, 148]. 
 
In addition to its 4 modules, CTGF contains a hinge region with a protease cleavage site 
that is sensitive to most proteases including elastases, matrix metalloproteinases 
(MMPs) and plasmin. The cleavage of the hinge region separates the N-domain from the 
C-domain resulting in two fragments of similar molecular weight. Plasmin, as well as 
chemotrypsin can also cleave module I and IV. Therefore, four different fragments of 
CTGF, in addition to the full-length protein, can be found in body fluids and in the 
supernatant of CTGF-producing cells (Fig. 4). It is postulated that these different 
fragments can fulfill different physiological functions [145, 148, 149]. The full length and 
C-terminus CTGF were reported to stimulate cell proliferation and collagen synthesis in 
different cells including fibroblasts. Also full length CTGF and module III were found to 
induce fibronectin synthesis and to mediate interaction with integrins, which is important 
for cell adhesion. They were also reported to induce the phosphorylation of extracellular 
signal-regulated kinases 1/2 (ERK1/2), which drive a signaling cascade that activates 
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collagen synthesis and induces fibrosis [150-152]. However, the induction of collagen 
synthesis by CTGF was found to be dependent on the presence of other factors like 
insulin and IGF, and is also tissue specific [148].  
 
2.7.2. Physiological functions of CTGF 
 
CTGF is known to play a vital role during the embryogenesis stage, since its absence 
was associated with malformation of cartilages, bones and blood vessels. However, 
CTGF expression and secretion continues during the adulthood [153, 154]. The structure 
of CTGF protein gives it the capacity to interact with several growth factors as well as 
cell surface and ECM proteins, allowing CTGF to function as a modulator for several 
cellular processes including cell migration, proliferation and differentiation, besides ECM 
synthesis and the cell-ECM interaction [155-157]. In addition, it was reported that CTGF 
mediates the deposition of fibronectin in response to TGF-β through upregulation of the 
active α5β1 integrin [158]. Based on the ability of CTGF to bind fibronectin and integrin 
on one hand, the ability to enhance the binding of fibronectin to fibrin on the other hand, 
it was proposed that CTGF promotes fiber-fiber, fiber-matrix and matrix-matrix 
interactions through direct interaction with ECM proteins [145].   
 
2.7.3. Role of CTGF in fibrotic heart disease 
 
CTGF and TGF-β are both upregulated in the myocardium of patients with HF, and are 
thought to play an important role in the pathogenesis of the disease, especially in the 
development of fibrosis [72]. Several publications have reported that CTGF mediates 
several functions of TGF-β. However, it was found that different CTGF fragments 
actually mediate different functions, that is, the N-terminal domain of CTGF mediates 
MyoF differentiation and collagen synthesis, while the C-terminal domain mediates the 
proliferation of fibroblasts [159]. Moreover, CTGF was shown to enhance the fibrotic 
process associated with HF, which was mainly dependent on its CT domain [160]. In 
addition, CTGF synergizes the ability of TGF-β to induce epithelial-mesenchymal 
transition (EMT), which is a known mechanism for the accumulation of fibroblasts in the 
site of injury and the later scar formation. Several mechanisms have been proposed with 
this respect, for example, it was shown that CTGF inhibits Smad7 phosphorylation, 
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which is a counter-regulatory mechanism for the activation of Smad2/3, the main second 
messengers for TGF-β signaling. Also it was found that CTGF enhances the binding of 
TGF-β to its own receptor and besides this there were some reports that CTGF induces 
the expression of the EMT marker tenascin-C (TN-C) [145, 161]. Moreover, it was found 
that CTGF is important for the expression of the stretched-induced fibrillary         
collagen α-1(III), MMPs and Ccl2/7/8 chemokines in primary CF, which are involved in 
fibrogenesis associated with cardiomyopathies [162].  
 
In contrast to the concept of the profibrotic role of CTGF, there are several recent 
publications reporting that CTGF has cardioprotective effects. Gravning and coworkers 
published two papers in the year 2011 and 2012 reporting that the over-expression of 
CTGF resulted in a diminished infarct size, but without a remarkable effect on the 
collagen content [163, 164]. Moreover, another two publications from the same lab in the 
year 2013 reported that CTGF overexpression has cardioprotective effects via 
attenuating the cardiac hypertrophy in response to chronic pressure-overload by either 
abdominal aortic banding or to chronic exposure to isoproterenol [165, 166]. A report 
from another lab in the year 2013 confirmed the cardioprotective effects of CTGF, and 
proposed that it increases the tolerance of cardiomyocytes towards hypoxia and 
oxidative stress via PI3-kinase (PI3K)-dependent Akt/GSK-3β signaling [167].   
 
2.7.4. Regulation of CTGF in CF 
 
CTGF is complexly regulated by different factors, including mechanical signaling, which 
can be transduced to the nucleus via certain cytoskeleton-dependent signaling involving 
integrins, and biochemical activation by autocrine and paracrine factors, like Ang II and 
TGF-β. In addition, functional Golgi apparatus was also found to play a role with this 
respect. Muehlich and coworkers reported a direct relationship between the formation of 
stress fibers and the expression of CTGF, which reflected an inverse relationship 
between the level of the monomeric G-actin and the level of CTGF expression. In 
addition, the overexpression of constitutively active RhoA, which is in favor of actin 
filaments formation, significantly enhanced the expression of CTGF. A similar induction 
of CTGF expression was also obtained with overexpression of the serum response 
factor (SRF) [168]. Several other reports demonstrated a regulatory role for the actin 
filaments on CTGF expression via mediating shear-stress signals to the nucleus and the 
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regulation of SRF [168, 169]. Moreover, as mentioned in section 1.6.2, the function of 
SRF requires the translocation of MRTF from the cytosol to the nucleus, where it 
complexes with SRF to function as transcription factor. However, it was also found that 
the monomeric G-actin binds MRTF in the cytosol, thus preventing it from translocation 
to the nucleus, and that the interaction between the monomeric G-actin and MRTF is 
dependent on the level of the monomeric G-actin in the cytosol, which is inversely 
related to the polymerization of actin filaments [138]. Taking these findings together, it 
can be concluded that for the induction of CTGF expression, actin polymerization is 
required, so that less G-actin is available in the cytosol in order to allow MRTF-SRF 
complex to form in the nucleus. In addition, it has been found that CTGF expression can 
be induced by a mechanism involving the activation of focal adhesion kinase (FAK), Src-
family of tyrosine kinases and PI3K, which translate the mechanical signaling by integrin 
and cytoskeleton into a change in CTGF expression [170].  
 
2.8. Aim of the project  
 
Cardiac fibrosis occurs a one major process in cardiac remodeling during heart disease. 
Within this process the numerical highly abundant CF secrete excessive amounts of 
extracellular matrix proteins as well as fibrosis-associated growth factors, cytokines and 
so called matricellular proteins. The connective tissue growth factor (CTGF) belongs to 
the latter protein family and has been shown to be strongly increased in its expression 
during cardiac fibrosis. The aim of this project was to unravel mechanisms, which are 
involved in the control of the expression and secretion of this protein in CF with a strong 
focus on calcium- and cytoskeleton-dependent mechanisms. In the detail, the 
angiotensin II-dependent regulation of the calcium handling in neonatal rat CF was 
studied, downstream mechanisms leading to a change in the regulation of CTGF were 













3.1.1. Chemicals, reagents and consumables 
 




tetrakis(acetoxymethyl ester) (BAPTA-AM) 
AAT Bioquest 
3-N-morpholino-propanesulfonic-acid (MOPS) AppliChem 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Carl Roth 
4',6-diamidino-2-phenylindole (DAPI) Roche 
Acetic acid (100%) Carl Roth 
Acrylamide rotiphorese gel 30 solution (30 % 




Ammonium persulfate (APS) AppliChem 
Angiotensin II, human (Ang II)  Sigma-Aldrich 
Aqua B. Braun  Braun 
Ascorbic acid AppliChem 
Bromophenol blue AppliChem 
Calcium chloride hexahydrate (CaCl2.6H2O) AppliChem 
Carbenicillin Applichem 
Cesium chloride (CsCl) Biomol 
Colchicine Cayman Chemicals 
Cyclosporin A (CsA)  Tocris 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich 
DMEM Glutamax, 1 g/l glucose, pyruvate Life Technologies 
DMEM Glutamax, 4.5 g/l glucose Life Technologies 
DNA loading buffer (6x) Thermo-Scientific 
DNase I type V Merck 
Ethanol, absolute  J.T. Baker 
Ethidium bromide Sigma-Aldrich 
Fetal calf serum (FCS) Life Technologies 
FITC-phalloidin Sigma-Aldrich 
Formaldehyde (37%) Merck 
Formamide Sigma-Aldrich 
GeneRuler 1 Kb DNA ladder Thermo-Scientific 
GeneRuler 1 Kb plus DNA ladder Thermo-Scientific 
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Glucose  AppliChem 
Glycerol AppliChem 
Glycine AppliChem 
Go 6983 Tocris 
gp91-ds-tat Mo BioTec 
gp91-ds-tat; sgp91 ds-tat, scrambled (Scr) Mo BioTec 
HEPES-buffered saline solution Lonza 
Igepal CA-630 Sigma-Aldrich 




Latrunculin-A (LAT-A) Cayman Chemicals 
Magnesium chloride (MgCl2)  AppliChem 
Magnesium sulphate monohydrate (MgSO4.H2O) AppliChem 
Manganese(II) chloride tetrahydrate (MnCl2.4H2O) AppliChem 
Methanol Carl Roth 
Methyl-beta-cyclodextrin (CDX)  Sigma-Aldrich 
Non-essential amino acids (NEAA) (100x) Life Technologies 
NSC 23766 Tocris 
Paraformaldehyde (PFA) Sigma-Aldrich 
Penicillin/streptomycin (P/S) (100x) Life Technologies 
Phosphate-buffered saline (PBS) without Ca2+ Life Technologies 
Picric acid Sigma-Aldrich 
Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) Carl Roth 
Polyfect Qiagen 
Ponceau S  Sigma-Aldrich 
Potassium chloride (KCl) AppliChem 
Potassium dihydrogen phosphate (KH2PO4)  AppliChem 
Pyrazol 3 (Pyr3)  Sigma-Aldrich 
Roti-block (10x)  Carl Roth 
Roti-immunoblock (10x) Carl Roth 
Roti-mark standard, protein molecular weight marker  Carl Roth 
Sodium acetate (CH₃COONa) AppliChem 
Sodium bicarbonate (NaHCO3)  Roth 
Sodium chloride (NaCl) AppliChem 
Sodium dihydrogen phosphate (NaH2PO4)  AppliChem 
Sodium dodecyl sulfate (SDS) AppliChem 
Sodium hydrogen phosphate dihydrate (Na2HPO4.2H2O)  AppliChem 
Sodium hydroxide (NaOH) AppliChem 
ß-Mercaptoethanol  AppliChem 
Tetramethylethylenediamine (TEMED) Merck 
Thapsigargin (TGN) Calbiochem 
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Tris ultrapure (Tris base) AppliChem 
TRITC-phalloidin Sigma-Aldrich 
Triton X-100  Carl Roth 
Trypan blue Fluka 
Trypsin  BD Biosciences  
Trypsin-EDTA 0.05% Life Technologies 
Trypsin neutralizing solution (TNS) Lonza 
Tryptone AppliChem 
Tween 20 Carl Roth 
U73122 (122)  Tocris 
U73343 (343)  Tocris 
Valsartan  Sigma-Aldrich 
Wheat germ agglutinin (WGA), Alexa-fluor 488 conjugate Life Technologies 
Yeast extract AppliChem 
Xestospongin C (XeC) Cayman Chemicals 






Cell culture dishes 6, 10, 15 cm Greiner Bio One 
Cell scrapers 1.7 cm blade Sarstedt 
Centrifuge tubes Polyallomer (16 x 102 mm) Beckman 
Dialysis device Float-A-lyzer G2, MWCO 20 KD Spectrum Labs 
Filter syringes Non pyrogenic, 0.2 µM Sarstedt 
Filtration sets 250, 500, 1000 ml, 0.22 µM Corning 
Flexitip pipette tips 0.5-200 µl Peqlab 
Micro-Amp optical adhesive 
films 
PCR compatible Applied Biosystens 
Micro-Amp optical reaction 
plates  
384-well Applied Biosystens 
Multi-well cell culture plates 6, 12, 24, 96-well Greiner Bio One 
Nitrocellulose membrane, 
Whatman, Protran 
Pore size 0.2 µM GE Healthcare 
PCR reaction tubes 0.2 ml Sarstedt 
Pipette tips  10, 100, 200 1000 µl Sarstedt 
Pipette tips with filters  10, 100, 200 1000 µl 4titude 
Reaction and centrifuge tubes  15, 50 ml Greiner Bio One 
Reaction tubes 0.5, 1.5, 2 ml Sarstedt 
Serological pipettes 1, 2, 5, 10, 25 ml Sarstedt 
Wide opening, serological 
pipettes 
10 ml Falcon 









AflII 10x NEB buffer 2 
New England Biolabs 
EcoRV 10x NEB buffer 3 
KpnI 10x NEB buffer 2 
PacI 10x NEB buffer 4 
PmeI 10x NEB buffer 4 
PstI 10x NEB buffer 3 
XhoI 10x NEB buffer 2 
SmaI 10x Tango yellow buffer  Thermo-Scientific 








5x HOT FIREPOL EvaGreen qPCR 
Mix Plus 
qPCR Solis Biodyne 
Exprep plasmid SV midi Midiprep plasmid 
purification from bacteria 
GeneAll 
Exprep plasmid SV mini Miniprep plasmid 
purification from bacteria 
GeneAll 
FGM-3 Bullet kit Culturing and 
maintenance of NHCF-V 
Lonza 
GoTaq green master mix PCR Promega 
High pure PCR product purification kit PCR product purification Roche 
Lumi-light western blotting substrate Chemiluminescence 
protein blot visualization 
Roche 
PrimeSTAR HS DNA polymerase Gene amplification by 
PCR 
TAKARA 
Quick ligation kit DNA ligation New England Biolabs 
Revert Aid First Strand cDNA 
Synthesis Kit  
RNA reverse 
transcription into cDNA 
Thermo-Scientific 
RNeasy Total RNA isolation Qiagen 
Screen Quest Fluo-8 No Wash Live cell Ca2+ imaging AAT Bioquest 
Super signal west femto maximum 
sensitivity substrate 
Chemiluminescence 
protein blot visualization 
Thermo-Scientific 










DH10B bacteria High-efficiency chemically competent cells for 
transformation  
AdEasier bacteria BJ5183 bacteria transformed with adenoviral 
backbone plasmid pAdEasy-1 
HEK293A Immortalized human embryonic kidney cell line 
Tsa201 Transformed HEK293 stably expressing SV40 
temperature-sensitive T antigen 
Primary neonatal rat cardiac 
fibroblasts (NRCF)  
Isolated weekly from neonatal Wistar rats (1-3 days 
old) 
Primary normal human 
ventricular cardiac fibroblasts 
(NHCF-V)  
Purchased from Lonza (catalogue No. CC-2904, Lot 
No. 351481), isolated from healthy 50 year old male 
donor. 






Ad.EGFP Susanne Lutz, Mannheim 
Ad.HA-CTGF Department of Life Science, Gwangju Institute of 
Science and Technology, South Korea 

























Caveolin-1 1:200 Not used Mouse  Monoclonal/7C8 sc-53564 Santa 
Cruz 
CTGF 1:200 1:50 Goat Polyclonal/L-20  sc-14939 Santa 
Cruz 

























1:2000 1:500 Mouse Monoclonal/B3 T9822 Sigma-
Aldrich 








Vimentin Not used 1:500 Mouse Monoclonal/ V9 V6630 Sigma-
Aldrich 
sm-actin  1:2500 Not used Mouse Monoclonal 1A4 A5228 Sigma-
Aldrich 













Dilution Source Catalogue No. Company 
Goat 1:10000 Donkey sc-2020 Santa Cruz 
Mouse 1:10000 Rabbit A9044 Sigma-Aldrich 
Rabbit 1:40000 Goat A9169 Sigma-Aldrich 






Dilution Fluorophore Source Catalogue 
No.  
Company 
































Table 9: Fluorophore-conjugated secondary antibodies for immunofluorescence 
 
 




Stock concentration Dilution 
DAPI 1 mg/ml 1:1000 
FITC-phalloidin 0.5 mg/ml 1:300 
TRITC-phalloidin 0.5 mg/ml 1:500 
Wheat germ agglutinin 
(WGA), Alexa-fluor 488 
conjugate 
1 mg/ml 1:200 
Table 10: Chemicals used for cell organelle/actin fluorescence staining  
 
 
















Primer Sequence (5`→ 3`) 
Amplification of CTGF gene 
without overhang 
Forward CTCTCCAAGAAGACTCAG C  
Reverse GCAGTTAGG AACCCAGATTTA  
      
Amplification of CTGF gene 
with the addition of KpnI 
and XhoI restriction sites 
Forward CCTGGTACCCTCGCCTCCGTCGCG 
Reverse AGACTCGAGGTCCCTTACTCCCTGGCTT  





Gene Primer Sequence (5`→ 3`) Annealing 
temperature 
CTGF Forward CCGGGTTACCAATGACAATA 58oC 
Reverse CACACCCCACAGAACTTAGC 
       
PBGD (housekeeping 
gene) 
Forward CCTGAAACTCTGCTTCGCTG 55, 57 or 
58oC Reverse CTGGACCATCTTCTTGCTGAA 
       
IP3R1 (variants 1, 2 
and 3) 
Forward AGCACCTTGGGCTTGGTTGATGA 57oC 
Reverse CCGTCCCCAGCAATTTCCTGTT 
       
IP3R2 Forward CAACGTCGGCCACTAGCTCTAAA 57oC 
Reverse AAGCTCCCCGTCTCTCACAGTTT 
       
IP3R3 Forward AGCAATGGGGATAACGTGGTTGTG 57oC 
Reverse GTCACAGGTCAGGAACTTCTCCT 
       
TRPC3 Forward ACTGGGCATGGGTAACTCAA 53oC 
Reverse TTCAGTTCACCTTCGTTCACCT 






pcDNA 3.1/Zeo(+)  Mammalian expression vector, allows high level of 
constitutive gene expression in mammalian cells  
pShuttle-CMV vector Facilitates the transfer of the gene of interest to AdEasier 
bacteria, where it can be recombined with the pAdEasy-1 
plasmid 
pAdEasy-1  E1 and E3 double deletion adenoviral backbone vector 


















GST-fish buffer (500 ml) 25 ml 1 M Tris (pH 7.4 with HCl) 
75 ml 1 M NaCl 
2 ml 1 M MgCl2 
50 ml glycerol  
5 ml Igepal CA-630 
up to 500 ml distilled water 
 
4x SDS-PAGE sample loading buffer without 
glycerol (50 ml) 
5 ml β-mercaptoethanol                                    
3.25 g SDS                                                    
15 ml 300 mM Tris (pH 6.8 with HCl)                     
0.125 g bromophenol blue                                       
up to 50 ml distilled water 
 
4x SDS-PAGE sample loading buffer with 
glycerol (50 ml) 
25 ml glycerol                                              
5 ml β-mercaptoethanol                               
3.25 g SDS                                                  
15 ml 300 mM Tris (pH 6.8 with HCl)                           
0.125 g bromophenol blue                                    
up to 50 ml distilled water 
 
10x TBS buffer (1000 ml) 12.12 g Tris 
87.65 g NaCl 
up to 1000 ml distilled water 
pH 7.4 with HCl 
 
TBS-T buffer (1000 ml) 1000 ml 10x TBS 
1 ml tween 20 
 
5x SDS-PAGE electrophoresis buffer (1000 
ml) 
15.1 g Tris 
94 g glycine 
5 g SDS 
up to 1000 ml distilled water 
pH 8.3 with KOH 
 
Blotting buffer (1000 ml) 3.02 g Tris 
14.4 g glycine 
200 ml methanol 
up to 1000 ml distilled water 
 
12 % SDS-polyacrylamide gel (50 ml) 16.5 ml distilled water 
20 ml acrylamide rotiphorese gel 30 
solution 
12.5 ml 1.5 M Tris (pH 8.8 with HCl) 
0.5 ml 10% SDS 
0.5 ml 10% APS 
0.02 ml TEMED 
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15% SDS-polyacrylamide gel (50 ml) 11.5 ml distilled water 
25 ml acrylamide rotiphorese gel 30 
solution 
12.5 ml 1.5 M Tris (pH 8.8 with HCl) 
0.5 ml 10% SDS 
0.5 ml 10% APS 
0.02 ml TEMED 
 
5% SDS-polyacrylamide gel (20 ml) 13.6 ml distilled water 
3.4 ml acrylamide rotiphorese gel 30 
solution 
2.5 ml 1 M Tris (pH 6.8 with HCl) 
0.2 ml 10% SDS 
0.2 ml 10% APS 
0.02 ml TEMED 
 
10% SDS (100 ml) 10 g SDS  
up to 100 ml distilled water 
 
10% APS (10 ml) 1 g APS 
up to 10 ml distilled water 
 
Ponceau S stain (100 ml) 5 ml glacial acetic acid 
0.2 g Ponceau S powder 
up to 100 ml distilled water 
 
Stripping buffer (500 ml) 3.79 g Tris 
3.9 ml β-mercaptoethanol 
10 g SDS 
up to 500 ml distilled water 




4% paraformaldehyde (PFA) (250 ml) 10 g paraformaldehyde 
50 µl 10 N NaOH 
25 ml 10x PBS 
up to 250 ml distilled water  
pH adjusted to 7.0 with HCl 
 
0.05% Triton (50 ml) 250 µl 10x Triton 
up to 50 ml PBS 
1x Roti-immunoblock (50 ml) 5 ml 10x Roti-immunoblock 










Formaldehyde (FA) agarose gel electrophoresis 
 
10x FA gel buffer (1000 ml) 41.46 g MOPS 
6.8 g sodium acetate 
2.9 g EDTA 
up to 1000 ml distilled water 
pH 7.0 with NaOH 
 
1x FA gel running  buffer (1000 ml) 100 ml 10x FA gel buffer 
20 ml 37% FA 
up to 1000 ml RNase-free water  
 
1.2% FA gel (100 ml) 1.2 g agarose 
10 ml 10x FA gel buffer 
up to 100 ml RNase-free water   
heat with mixing, cool to 65oC, add    
1.8 ml 37% FA and 3 µl ethidium 
bromide (10 mg/ml) then cast 
 
5x RNA loading buffer (10 ml) 16 µl saturated aqueous bromophenol 
blue solution 
80 µl 500 mM EDTA (pH 8.0 NaOH) 
720 µl 37% FA 
2 ml glycerol anhydrous 
3.084 ml formamide 
4 ml FA gel buffer 
up to 10 ml RNase-free water 
  
DNA agarose gel electrophoresis 
 
1% DNA agarose gel (50 ml) 0.5 g agarose powder 
50 ml 1x TAE buffer 
2 µl ethidium bromide (10 mg/ml) 
 
50x TAE buffer (1000 ml) 242.28 g Tris 
57.1 ml glacial acetic acid 
200 ml 0.25 M EDTA (pH 8.0 with 
NaOH) 
up to 1000 ml distilled water 
 
Bacterial culture media and plates 
 
LB medium (1000 ml) 10 g tryptone 
5 g yeast extract 
10 g NaCl 






LB agar plates with carbenicillin (1000 ml) 10 g tryptone 
5 g yeast extract 
10 g NaCl 
15 g agar 
up to 1000 ml distilled water 
pH 7.0 with NaOH 
autoclave  
let cool to about 50oC, then add 1 ml 
carbenicillin stock (50 mg/ml), then cast 
as 20 ml/10 cm petri dish 
 
LB agar plates with kanamycin (1000 ml) 10 g tryptone 
5 g yeast extract 
10 g NaCl 
15 g agar 
up to 1000 ml distilled water, pH 7.0 
autoclave  
let cool to about 50oC, then add 1 ml 
kanamycin stock (33 mg/ml), then cast 
as 20 ml/10 cm petri dish 
SOB medium (1000 ml) 20 g tryptone 
5 g yeast extract 
0.5 g NaCl 
10 ml 25 mM KCl 
up to 1000 ml distilled water 
pH 7.4 
autoclave 
5 ml autoclaved 2 M MgCl2 
 
SOC medium (100 ml) 1 ml filter-sterilized 2 M glucose 
up to 100 ml SOB medium 
 
0.5 M PIPES buffer (20 ml) 3.02 g PIPES 
up to 20 ml distilled water 
pH 6.7 with NaOH 
 
Inoue buffer (10 ml) 108.8 g MnCl2.4H2O 
22 mg CaCl2.6H2O 
186 mg KCl 
200 µl 0.5 M PIPES 















Calcium- and bicarbonate- free Hanks with 
HEPES (CBFHH) (1000 ml) 
40 ml NaCl stock (200 g/l)                           
10 ml MgSO4.H2O stock (20 g/l)                  
10 ml KH2PO4 stock (6 g/l)                         
10 ml Na2HPO4.2H2O stock (5.97 g/l)       
10 ml glucose dihydrate stock (100 g/l)      
100 ml HEPES stock (47.66 g/l)                              
up to 1000 ml distilled water, sterile by 
filtration 
pH 7.4 with NaOH  
 
50x trypsin stock solution (10 ml) 1 g trypsin/10 ml CBFHH, dissolved 
overnight at 4oC with continuous 
rotation, sterilized by filter syringe (0.2 
µM) 
 
DNase I stock solution (100 ml) 100 mg DNase I type V/100 ml distilled 
water 
 
Heat inactivated FCS (50 ml) 50 ml FCS was incubated in a water 
bath adjusted to 56oC for 30 min, during 
which it was shaken gently every 5 min. 
   
Non-cardiomyocyte medium (NKM) 500 ml DMEM GlutaMax 1 g/l glucose 
50 ml heat-inactivated FCS 
5 ml P/S (100x) 
 
Trypsin working solution (50 ml) 0.5 ml P/S (100x) 
1.3 ml trypsin stock 
0.2 ml DNase I stock  
up to 50 ml CBFHH 
 
DNase-working solution (50 ml) 0.5 ml P/S (100x) 
1.7 ml FCS 
0.2 ml DNase I stock 
up to 50 ml CBFHH 
 
0.4% Trypan blue (100 ml) 0.4 mg trypan blue 
100 ml distilled water 
NRCF culture media 
 
Fibroblasts growth medium (FGM) 500 ml DMEM GlutaMAX 4.5 g/l 
glucose 
50 ml FCS 
5 ml P/S (100x)  




Low medium (LM) 500 ml DMEM GlutaMax 1 g/l glucose 
5 ml P/S (100x)  
HEK293A culture media 
 
HEK293A growth medium 500 ml DMEM GlutaMAX 4.5 g/l 
glucose 
50 ml heat-inactivated FCS 
5 ml P/S (100x) 
  
HEK293A low serum medium 500 ml DMEM GlutaMAX 4.5 g/l 
glucose 
2.5 ml heat-inactivated FCS 
5 ml P/S (100x) 
  
Buffers for adenovirus purification 
 
10x Virus storage buffer (VSB) (1000 ml) 100 ml 1 M Tris, (pH 7.4 with HCl) 
80 g NaCl 
50 ml 1 M KCl 
10 ml 1 M MgCl2 
up to 1000 ml distilled water 
 
Light cesium chloride (CsCl) (1.209 g/ml) 11.02 g CsCl, fill up to 50 g 1x VSB 
 
Heavy cesium chloride (CsCl) (1.459 g/ml) 21.10 g CsCl, fill up to 50 g 1x VSB 
 
Sirius red-based colorimetric microassay for collagen 
 
Sirius red solution (100 ml) 100 mg siruis red dye powder 
100 ml saturated aqueous picric acid 
 
Bouin's solution (16 ml) 
 
 
15 ml saturated aqueous picric acid 
5 ml 35% formaldehyde 
1 ml 100% acetic acid 
 
Other buffers and solution 
 
Calcium-free Tyrode's solution (500 ml) 20 ml stock I (175 g NaCl, 10 g KCl,   
25 ml MgCl2, up to 1000 ml distilled 
water) 
19 ml stock II (50 g/l NaHCO3) 
10 ml stock III ( 5.8 g/l NaH2PO4) 
0.5 g glucose 
50 mg ascorbic acid 
up to 500 ml distilled water 
 
3 M Sodium acetate (1000 ml) 246 g sodium acetate 
up to 1000 ml distilled water 
pH 5.2 with acetic acid 










in cell culture 
Control 
condition 
BAPTA-AM 13.1 mM DMSO 7 µM DMSO 
Colchicine 2.5 mg/ml Water 1.3, 5 µg/ml Water 
Cyclosporin A (CsA)  40 mM DMSO 20 nM DMSO 
Go 6983 50 mM DMSO 6 µM DMSO 
gp91 ds-tat 50 mM Water 5 µM  Water 
gp91 ds-tat; sgp91 ds-tat, 
scrambled 
50 mM Water 5 µM  Water 
Kn-92 1 mM Water 2 µM  Water 
Kn-93 1 mM DMSO 2 µM  DMSO 
Latrunculin-A (LAT-A) 100 µg/ml Ethanol, 
absolute 








Water 2.5 mM Water 
NSC 23766 50 mM Water 50 µM Water 
Pyrazol 3 (Pyr3)  10.95 mM DMSO 3 µM   DMSO 
Thapsigargin (TGN) 1 mM DMSO 3 µM DMSO 
U73122 (122)  5 mM DMSO 1.5 µM  DMSO 
U73343 (343)  5 mM DMSO 1.5 µM  DMSO 
Valsartan 2.3 mM DMSO 15 nM DMSO 
Xestospongin C (XeC) 5.6 mM Ethanol, 
absolute 
1.4, 100 µM Ethanol, 
absolute 
Table 16: End concentration in cell culture for each of the used inhibitors 
 
 





Autoclave  VX-150 Systec 
Cell counter Casy Roche 
Cell counting chamber Fuchs-Rosenthal bright-line Marienfeld-Superior 
Cell culture incubator  Steri-cult 200 Incubator  Forma Scientific 
Cell culture incubator  Labotect Incubator C 200  Labotect 
Cell sieve Cell dissociation sieve - 
tissue grinder kit (250 µm 
pore size) 
Sigma-Aldrich 
Centrifuge bench top Centrifuge 5804 R  Eppendorf 
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Centrifuge bench top Sigma 3K30 Sigma 
Centrifuge table top Tabletop centrifuge 5415 D  Eppendorf 
Centrifuge table top  Combi-spin FVL-2400N Biosan 
Centrifuge table top Centrifuge 5417 R Eppendorf 
Chemiluminescence imaging 
system 
Versa doc MP Bio-Rad 
Double distilled water system Milli-Q Millipore 
Electric power supply and control Powerpac Bio-Rad 
Heating block Thermo mixer compact Eppendorf 
Horizontal system for submerged 
gel electrophoresis   
H5 BRL 
Horizontal system for submerged 
gel electrophoresis   
Mini-sub cell GT Bio-Rad 
Incubator CFC-free Sanyo 
Inverted fluorescence microscope Axiovert 200 Zeiss 
Inverted fluorescence microscope 
with climate chamber 
Olympus IX 81 Olympus 
Inverted microscope Axiovert S100 TV Zeiss 
Microscope camera CAM-XM10-T-Camera Olympus 
Microscope filter Cy5 BP 635/40 Olympus 
Microscope filter DAPI BP 403/12 Olympus 
Microscope filter EGFP BP 470/20 Olympus 
Microscope filter FITC BP492/18 Olympus 
Microscope filter Texas Red BP 572/23 Olympus 
Microscope objective 20x LUCPLFLN20xPH|0.45  Olympus 
Microscope objective 40x LUCPLFLN40xPH|0.60 Olympus 
Microscope objective 60x PlanApo N60x/1.42 oil Olympus 
pH meter WTW Inolab 
Pipettes   Pipetman Gilson 
Plate reader FlexStation3 Molecular Devices 
Pump ME2 Vacuubrand 
Real-Time-PCR-System TaqMan 7900HT Fast Real-
Time-PCR System 
Applied Biosystems 
Rocker Diomax 1030 Heidolph 
Rotation shaker Reax 3 Heidolph 
Scale Portable Sartorius 
Shaker GFL 3016 GLF 
Shaker Vibramax 100 Heidolph 
Shaking incubator Innova 4300 New Baunswick 
Scientific 
Sonicator Sonifier B-12 Branson Sonic 
Power  
Spectrophotometer Nanodrop 1000  Peqlab 
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Temperature control chamber Certomat B. Braun 
Thermocycler  Mastercycler gradient  Eppendorf 
Ultracentrifuge L8-70M Beckman 
Ultracentrifuge rotor SW-27 Beckman 
UV agarose gel imaging system Gel doc XR Bio-Rad 
UV lamb plate TI 1 Biometra 
Vortexer VF 2 Vortexer  Janke u. Kunkel IKA 
Labortechnik 
Water bath  2764 Eppendorf 
Western blot gel electrophoresis 
and protein blotting system 
Mini-protean tetra cell 4-gel 
system 
Bio-Rad 






GraphPad prism 5.0 Statistical calculations and 
graphs drawing 
GraphPad 
Image J 1.60_20, time series 
analyzer V2.0 plug-in 
Evaluation of fluorescence 
intensity 
National Institutes 
of Health, USA  
Quantity One 4.6.5 Operating the Versa doc MP 
system and for semi-
quantification of western blots 
Bio-Rad 
SDS 2.4 Operating the TaqMan 7900HT 
Fast Real-Time-PCR System, 
and its data analysis 
Applied Biosystems 
Xcellence pro Operating the Olympus 
microscopy system for cell 
imaging 
Olympus 






3.2.1. Isolation, maintenance and passaging of primary neonatal rat cardiac 
fibroblasts 
 
Neonatal rat cardiac fibroblasts (NRCF) were isolated from neonatal rats (1-3 days old) 
according to a modified protocol by Simpson and Savion, 1982 [171]. Briefly, the animals 
were decapitated, the thoracic cavity was quickly opened and the hearts were removed. 
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The pedicles and the atria were removed, and the ventricles were cut into small pieces 
(about 1-2 mm size). After that, the cardiac cells were released from the ventricular 
tissues by repeated digestion cycles. To do so, the ventricular tissues were incubated 
with trypsin working solution with mild rocking at room temperature until it started to 
become cloudy (1-4 min), at this point, the supernatant solution was transferred into a 
collecting tube containing fetal calf serum (FCS), and DNAse I working solution was 
added to the tissues. The tissues were triturated several times to physically release the 
loosened cells. Then, the supernatant was transferred into the collecting tube, and a new 
digestion cycle was started. The digestion cycles continued until no more cells were 
released. After that, the collecting tubes were centrifuged at 60 g, 4oC for 15 min, the 
supernatant was aspired, the pellets were resuspended in non-cardiomyocyte medium 
(NKM), and the cells from different collecting tubes were pooled together. Next, the cells 
were strained through a pre-wetted cell sieve (250 µm pore size), and were collected in 
a new 50 ml reaction tube. After that, a sample from the cell suspension was mixed with 
0.4% trypan blue as 1:1, and the mixture was then transferred into Fuchs-Rosenthal 
bright-line cell counting chamber to determine the number and viability of the yielded 
cells. Finally, NRCF were isolated from cell suspension by making use of their ability to 
adhere much faster to plastic cell culture surfaces comparing to cardiomyocytes and 
other cell types. To do so, the cell suspension was diluted with an appropriate volume of 
NKM, and the cells were seeded on 15 cm cell culture dishes as 10 million cells/dish. 
The cells were incubated at 37oC, 5% CO2, 99% humidity for 1 hr, after which the 
medium containing the non-adherent cells was changed for fibroblasts growth medium 
(FGM). By this, most of the adherent cells are NRCF, and these cells are considered 
passage 0 (P0). The cells were maintained in FGM until the desired confluency had 
been reached.  
 
Confluent NRCF culture plates were washed twice with pre-warmed PBS, after that, they 
were incubated with pre-warmed 0.05% trypsin-EDTA (7 ml/15 cm dish) until the cells 
started to round up and detach, at this point 20 ml/15 cm dish FGM was added, and the 
cells were collected in 50 ml reaction tube, diluted further with FGM, triturated well and 
seeded in new cell culture dishes and plates, so that the splitting ratio was 1:4 with 





Usually 24 hr before running any experiment, the cells were washed twice with PBS, and 
the FGM was exchanged by low medium (LM). This step was referred to as starvation. 
 
 
3.2.2. Culturing, maintenance and passaging of primary normal human 
ventricular cardiac fibroblasts (NHCF-V) 
 
Handling of NHCF-V cells was according to the instructions of the supplier company, 
using the media and solutions supplied with the cells. To do so, the frozen components 
of the FGM-3Bullet kit (FCS, recombinant human insulin, recombinant human fibroblast 
growth factor, and gentamycin/amphoteracin) were thawed on ice and combined with the 
supplied basal medium.  
 
FGM-3Bullet medium was added first into the culture vessels as 1 ml/5 cm2, and was 
allowed to equilibrate in the cell culture incubator for at least 30 min. After that, the 
cryovial of the NHCF-V cells was quickly thawed in a water bath set to 37oC, the cells 
were resuspended in the cryovial and dispensed into the equilibrated cell culture 
vessels.  
 
The cells were passaged when they had already reached 70-80% confluency. FGM-
3Bullet medium was added first into the culture vessels as 1 ml/5 cm2, as was allowed to 
equilibrate in the cell culture incubator for at least 30 min. The medium on the cells was 
removed and the cells were washed two times with room temperature HEPES-buffered 
saline solution. After that, trypsin-EDTA was added only enough to cover the cell culture 
surface, and the cells were incubated at room temperature until most of the cells had 
already detached from the vessel. At this point, room temperature trypsin neutralizing 
solution (TNS) was added in a volume equivalent to two times that of the already added 
trypsin-EDTA. The cell suspension was collected and diluted with the appropriate 









3.2.3. Culturing, passaging and maintenance of HEK293A cells 
 
The cryovials of HEK293A cells were thawed quickly in 37oC water bath, and were 
directly diluted with an appropriate volume of HEK293A growth medium. After that, the 
cells were seeded in 15 cm dishes, and the medium was exchanged every other day. 
When the cells were 70-80% confluent, they were passaged. To do so, the cells were 
washed twice with pre-warmed PBS, after that, they were incubated with pre-warmed 
7ml 0.05% trypsin-EDTA until the cells started to round up and detach, at this point 
HEK293A growth medium was added, the cell suspension was collected in 50 ml 
reaction tube and diluted with the appropriate volume of HEK293A growth medium. The 
cell suspension was triturated well, and was then dispensed in new cell culture dishes 
and plates according to the desired splitting ratio. 
 
In case of passaging HEK293A cells for transfection, a serial dilution from the cell 
suspension was performed and seeded in cell culture plates so that on the next day, the 
plates with the appropriate cell confluency could be used.  
 
 
3.2.4. Live cell calcium imaging and time lapse analysis 
 
Generally, experiments were performed in 12-well plates. The cells were initially 
incubated separately with 570 µl medium containing the experimental conditions for 1 hr, 
unless otherwise indicated. After that, 60 µl/well of the Ca2+ sensitive fluorescent dye 
solution was added, and the cells were incubated with the dye for 25-30 min in the 
climate chamber of the inverse fluorescence microscope (Olympus), where the 
conditions were adjusted to 37oC, 5% CO2, 57.37% lamp intensity and the exposure time 
to 290 millisecond. The 20x objective and the GFP filter were used to visualize the cells. 
Time-lapse recording was programmed as one frame every 5 sec for a duration of 5 min, 
with the first frame taken at 0 second. Ang II (100 nM) was added at the 20th second 
(after the first five frames), unless otherwise indicated. The change in fluorescence 
intensity for individual cells, which correlates to the change in cytoplasmic Ca2+ level, 
was analyzed with the help of Image J, using time series analyzer version 2 plug-in. For 
each experiment, several fields from different wells were analyzed with at least 70 cells 
per field. For all of the Ca2+ transient assays, the baseline fluorescence (first 5 frames 
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before the addition of Ang II) was subtracted from the graph to normalize the 
background fluorescence, unless otherwise indicated. The change in the maximal 
fluorescence intensity (ΔRFUMax) was used to compare the effect of different conditions 
on the intensity of the Ca2+ transient. The percentages of the Ca2+ oscillating cells and 
the cell with mitochondrial Ca2+ loading were determined by manual counting.  
 
 
3.2.5. Fluorescence staining for cell microscopy 
 
After cells were incubated overnight with the treatment conditions, the medium was 
aspired and the cells were fixed with 4% paraformaldehyde (PFA) for 15 min at room 
temperature. After that, they were washed three times with PBS, and incubated for 5 min 
with 0.05% Triton solution to permeabilize the cellular membranes, this was followed by 
washing three times with PBS and incubation with 1x Roti-immunoblock for 1 hr at room 
temperature. Then, the cells were incubated with PBS containing the antibody against 
the protein(s) of interest (using the dilutions shown in table 7), DAPI to stain the nuclei, 
and when needed fluorophore-conjugated-phalloidin to stain actin and fluorophore-
conjugated WGA to stain the cellular membranous structures including the Golgi 
apparatus (using the dilutions shown in table 10). The cells were incubated with this 
solution overnight at 4oC shuttle shaking and protected from light. On the next day, the 
cells were washed three times with PBS, and were incubated with the appropriate 
fluorophore-conjugated secondary antibodies (using the dilutions shown in table 9) for   
1 hr at room temperature while shaking and protected from light. At the end, the cells 
were washed three times with PBS and were imaged by inverse fluorescence 
microscopy (Olympus). 
   
 
3.2.6. Sirius red-based colorimetric microassay for collagen 
 
The assay was performed using 12-well plates of confluent NRCF according to the 
protocol described by Tullberg-Reinert and Jundt [172]. Following cell treatment, the 
medium was removed and the cells were washed three times with PBS followed by 1 hr 
incubation at room temperature with Bouin’s solution for fixation (1 ml/well). After that, 
Bouin’s solution was removed and the plates were washed with running tap water for   
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15 min, followed by air drying. When the plates were completely dry, 1 ml/well of sirius 
stain solution was added and the cells were stained for 1 hr under mild shaking. After 
that, the dye was removed and the cells were washed extensively with 0.01 N HCl to 
remove the excess dye. Then, each well received 0.4 ml of 0.1 N NaOH, and the plate 
was placed on a shaker for 30 min at room temperature to dissolve the dye. Finally, the 
dissolved dye was transferred into a 96-well plate, and the absorbance was measured at 
550 nm wave length against 0.1 N NaOH using FlexStation 3 plate reader.  
 
 
3.2.7. Protein biochemical analysis 
 
 
3.2.7.1. Preparation of samples for immunoblotting 
 
Generally, NRCF were initially incubated with the inhibitor in question (according to the 
concentrations shown in table 16) or the corresponding control condition for 1 hr, before 
Ang II (100 nM) was added. After about 24 hr, the conditioned medium was collected and 
kept on ice, and ice-cold GST-fish lysis buffer was used to lyse the cells with the help of 
cell scrapers. Then, the scraped cells were centrifuged at 13000 g for 5 min to remove cell 
debris, and the supernatant was mixed as 1:4 with the 4x sample loading buffer without 
glycerol. Medium samples were mixed as 1:4 with the 4x sample loading buffer containing 
glycerol. After that, the samples were incubated at 95oC for 5 min on a heating block, then 
on ice for few minutes, and finally they were centrifuged briefly and kept cooled until use. 
 
In case of checking protein phosphorylation, the cell lysates were quickly collected 5 min 
after Ang II treatment, using 1x SDS sample loading buffer containing glycerol, because 
SDS instantly denature proteins, thus blocking the activity of phosphatases. Since the     
1x SDS sample loading buffer can also disrupt the nuclear envelope resulting in the 
release of DNA, which makes the samples very viscous, the samples were exposed to 
three cycles of sonication on ice each lasted for 15 sec, with the output knob adjusted to 4. 
After that, the samples were incubated at 95oC for 5 min on a heating block, then on ice for 





3.2.7.2. Protein separation, by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), and blotting  
 
Protein samples mixed with loading buffer were loaded on 15% or 12% SDS-
polyacrylamide gels (table 15), depending on the molecular weight of the investigated 
proteins. The electrophoresis was performed with 200 volts for 70 min. After that, the 
proteins were blotted onto nitrocellulose membranes for 1 hr under cooled conditions with 
100 volts. Then, the nitrocellulose membranes were incubated for 5 min in Ponceau S 
stain at room temperature to stain the proteins on the membrane and to visualize the 
protein marker. The excess dye was washed off several times with distilled water, and 
when necessary the membranes were cut according to the protein marker to allow the 
incubation with different primary antibodies. The membranes were destained by washing 
several times with TBS-T, followed by incubation with 1x Roti-block for 1 hr at room 
temperature. After that, they were washed three times with TBS-T, each for 5 min followed 
by overnight incubation with the appropriate primary antibodies (diluted with TBS-T as 
shown in table 7) at 4oC with shaking. On the next day, the membranes were washed 
three times with TBS-T each for 5 min, and then, they were incubated with the appropriate 
HRP-conjugated secondary antibodies (diluted with TBS-T as shown in table 8) for 1 hr, at 
room temperature with shaking. After that, the membranes were washed three times with 
TBS-T, each for 5 min, and at the end the protein antibody complexes were visualized by 
Versa doc MP chemiluminescence detection system using lumi-light western blotting 
substrate kit or super signal west femto maximum sensitivity substrate kit. 
 
3.2.7.3. Exchanging antibodies from nitrocellulose membranes 
 
In the first step, the existing antibodies were stripped from the nitrocellulose membranes. 
To do so, the membranes were incubated with the stripping buffer for exactly 30 min at 
50oC with shacking. After that, the membranes were washed 6 times with TBS-T buffer 
each for 10 min at room temperature. Then, the membranes were incubated with a 
blocking solution and the proteins were labelled with the primary and secondary as 





3.2.8. Molecular biology 
 
3.2.8.1. Determination of relative change in gene expression  
 
3.2.8.1.1. RNA isolation 
 
The experiments were performed using confluent 10 cm dishes of NRCF. Following 
treatment course, the cells were washed once with PBS, and were incubated afterwards 
with 0.05 % trypsin-EDTA (2.5 ml/plate) for 3-4 min until most were detached. At this 
point, 12 ml FGM was added and the cell suspension was collected and centrifuged at 
300 g for 5 min at 4oC. The supernatant was removed completely, and the total RNA 
was extracted from the cell pellet using RNeasy kit according to the manufacturer’s 
instructions. Following RNA extraction, the RNA concentration was determined using 
Nanodrop 1000 device. 
    
3.2.8.1.2. RNA analysis by formaldehyde (FA) agarose gel-electrophoresis 
 
RNA analysis was performed according to the protocol described in the RNeasy kit 
manufacturer’s instructions. First, 1.2% FA agarose gel was prepared as described in 
section 2.1.7. After the gel had already condensed, it was incubated for at least 30 min 
in a horizontal system for submerged gel electrophoresis containing 1x FA gel running 
buffer, to equilibrate before sample loading. RNA samples were diluted with RNase-free 
water and were mixed with 5x RNA loading dye. Usually between 0.5 to 2.5 µg RNA was 
used from each sample. After that, the RNA samples were incubated for 5 min at 65oC 
for 5 min, then, chilled on ice, centrifuged briefly and loaded onto the equilibrated 1.2% 
FA agarose gel. The electrophoresis was performed at 7 volts/cm for 25-30 min. Finally, 
the RNA bands were imaged with the help of Gel doc XR device. The detection of two 
sharp bands, which reflects the ribosomal RNAs, was considered as an indication of a 






3.2.8.1.3. RNA reverse transcription into cDNA 
 
Every time, 1000 ng RNA was used from each sample to produce cDNA using Revert 
Aid First Strand cDNA Synthese Kit according to the manufacturer’s instructions.  
 
3.2.8.1.4. Quantitative polymerase chain reaction (qPCR) 
 
The qPCR was performed using 5x HOT FIREPOL EvaGreen qPCR Mix Plus kit, 
according to the instructions of the manufacturer. The cDNA samples were diluted as 
1:20, and the primers for each gene were diluted to 10 µM. A master mix for each target 
gene was prepared by scaling up the recipe shown in table 19 according to the number 





Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 




Tables 19: Mix for a single replicate  
 
The experiment was performed in a Micro-Amp optical reaction 384-well plate, where 
first 1 µl of the diluted cDNA was added per well, followed by the addition of 19 µl of the 
corresponding master mix. After loading the samples on the plate, it was sealed with 
Micro-Amp optical adhesive film and centrifuged for 5 min at 700 g. Finally the reaction 
was performed using TaqMan 7900HT Fast Real-Time-PCR System, according to the 




Cycle Temperature  Time  Repetition Ramp 
rate 
I Initial denaturation 95oC 15 min 1 time 
1.6oC/sec II 
Denaturation 95oC 15 sec 




Elongation 72oC 45 sec 
III Dissociation curve 95oC 15 sec 1 time 
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 60oC 15 sec 
95oC 15 sec 
Table 20: General qPCR program 
 
 
3.2.8.2. RT-PCR for verification of gene expression 
 
To check whether a certain gene is expressed in NRCF, cDNA was first synthesized 
from RNA, followed by a PCR step according to the reaction mixture shown in table 21, 





Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
GoTaq green master mix 12.5 
cDNA 1 
Water 9.5 
Table 21: Reaction mixture for the PCR step 
 
 
The reaction was performed using Mastercycler gradient device according to the 




Temperature (oC) Time  Repetition 
Initial denaturation 94 2 min 1 time 
Denaturation 94 10 sec 
45 times Annealing Specified for each gene 5 sec 
Elongation 72 85 sec 
Final elongation 72 10 min 1 time  
Table 22: General program for the PCR step  
 
 
After that, the PCR product was separated by DNA-agarose gel electrophoresis, and the 






3.2.8.3. Construction of an adenovirus for overexpression of tetracysteine (TC) 
tagged CTGF 
 
3.2.8.3.1. Restriction digestion 
 
The conditions and the composition of the reaction mixture for the restriction digestion 
were according to the manufacturer’s instructions, provided with each restriction 
enzyme. 
 
3.2.8.3.2. DNA agarose gel electrophoresis 
 
DNA samples were pre-mixed with a suitable volume of 6x DNA loading buffer. After 
that, they were loaded on a DNA agarose gel. The electrophoresis was performed at      
7 volts/cm for 15-35 min, depending on the expected size of DNA band. After that, DNA 
bands were imaged with the help of Gel doc XR device.  
 
3.2.8.3.3. Purification of DNA from agarose gel 
 
After performing DNA agarose gel electrophoresis for PCR products or restriction 
digests, the regions of the agarose gel containing the DNA bands were excised under 
UV light using a sharp scalpel. After that, the DNA was extracted using High pure PCR 
product purification kit according to the manufacturer’s instructions. 
 
3.2.8.3.4. Amplification of CTGF gene from cDNA by PCR 
 
As a starting point, cDNA prepared by reverse transcription of total NRCF RNA, was 
used as a template for CTGF gene amplification, using PrimeSTAR HS DNA polymerase 
kit. The reaction mixture was prepared according to table 23, and the PCR was 











cDNA 2 µl 
5x PrimeSTAR buffer (Mg 2+ plus) 10 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
dNTP mixture (2.5 mM each) 4 µl 
PrimStar HS Polymerase 0.5 µl 
Water 31.5 µl 
Final volume 50 µl 





Temperature (oC) Time  Repetition 
Denaturation 95 10 sec 
30 times Annealing 55 5 sec 
Elongation 72 85 sec 
Table 24: PCR program for CTGF gene amplification from cDNA  
 
 
3.2.8.3.5. Addition of KpnI and XhoI restriction sites to CTGF gene by PCR 
 
After amplification of the CTGF fragment, it was purified as mentioned before, and was 
further amplified using primers with overhangs, which can add KpnI and XhoI restriction 
sites at the 5’ and 3’ ends of the gene, respectively. The reaction mixture was prepared 





CTGF fragment (109 ng/µl) 1 µl 
5x PrimSTAR buffer (Mg 2+ plus) 10 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
dNTP mixture (2.5 mM each) 4 µl 
PrimStar HS Polymerase 0.5 µl 
Water 32.5 µl 
Final volume 50 µl 
Table 25: PCR reaction mixture for the addition of restriction sites to the ends of CTGF 
gene by PCR 
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Cycle Temperature (oC) Time  Repetition 
Denaturation 95 10 sec 
30 times Annealing 55 5 sec 
Elongation 72 70 sec 
Table 26: PCR program for the addition of restriction sites to the ends of CTGF gene 
 
 
3.2.8.3.6. Hybridization of TC-tag oligonucleotides 
 
The TC-tag was provided as separate sense and antisense DNA oligonucleotides. The 
lyophilized powder of each oligonucleotide strand was reconstituted in water to achieve 
a concentration of 1 pmol/µl. Equal number of moles from each oligonucleotide was 
used in the hybridization reaction as shown in table 27. The hybridization mixture was 
incubated at 95oC for 30 min, and then, it was left to cool down slowly overnight to room 
temperature. 
 
 Table 27: Hybridization reaction for TC-tag oligonucleotides 
 
 
3.2.8.3.7. DNA ligation 
 
Quick ligation kit was used to perform different kinds of ligation reactions, according to 
the manufacturer’s instruction. For cohesive end ligation 3:1 molar excess of the insert 
was used, whereas for linker ligation 20:1 molar excess of the linker was used. As a 
negative control, equal volume of water was used instead of the insert. The ligation 
reaction mixture was incubated for 1 hr at room temperature, after that, it was directly 





Sense oligonucleotide  16.25 µl (16.25 pmol) 
Antisense oligonucleotide 16.25 µl (16.25 pmol) 
NEB Buffer 1 5 µl 
Water 12.5 µl 
Final volume 50 µl 
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3.2.8.3.8. Transformation of DH10B bacteria by heat shock protocol 
 
Initially DH10B bacteria were thawed on ice for 30 min. After that, 25 ng of the 
transforming DNA was mixed well with 50 µl of the bacteria in pre-cooled tubes, and the 
tubes were incubated on ice for 30 min. Then, the tubes were incubated in a 42oC water 
bath for exactly 90 sec, after which they were rapidly transferred into an ice bath, where 
they were incubated for 2 min. In the next step, 800 µl of SOC medium was added to 
each tube, warmed to 37oC in a water bath, and then, transferred to a shaking incubator 
set to 37oC. The Bacteria were incubated for 45 min whilst continuous shacking. After 
that, under sterile conditions 200 µl of the bacterial culture was transferred to each       
10 cm LB agar plate supplied with the appropriate antibiotic. The bacterial suspension 
was distributed evenly throughout the plate, and was left until the liquid was absorbed. 
Finally, the plates were transferred in an inverted position to a 37oC incubator. On the 
next day, the colonies of bacteria that grew on the plates were picked up under sterile 
conditions and each colony was used to inoculate LB medium containing the proper 
antibiotic.     
 
3.2.8.3.9. Transformation of AdEasier cells by Inoue protocol 
 
A starter culture was made by adding 10 µl AdEasier cell stock to 5 ml of LB medium 
(containing 50 µg/ml carbenicillin), and was placed in a shaking incubator at 37oC for     
8 hr. After that, an overnight culture was prepared by adding the starter culture to 120 ml 
SOB medium (containing 50 µg/ml carbenicillin). The culture was placed in a shaking 
incubator at 18-22oC overnight and until the optical density at a wave length of 600 nm 
(OD600) was between 0.45-0.50. At this point, the bacterial suspension was centrifuged 
for 10 min at 4oC and 2500 g, and the supernatant was poured off completely. Then, the 
bacterial pellet was resuspended in 8 ml of ice-cold Inoue buffer, and was centrifuged for 
10 min at 4oC and 2500 g. Next, the supernatant was poured off completely, the 
bacterial pellet was resuspended in 2 ml of fresh ice-cold Inoue buffer, and the cells 
were immediately transformed with the vector of interest by heat shock method as 
described above.  




3.2.8.3.10. Isopropanol precipitation of DNA 
 
DNA solution was mixed with 0.1 volume of 3 M sodium acetate solution (pH 5.2) and 
0.7 volume of room temperature isopropanol, and incubated overnight at 80oC. The next 
day, the solution was centrifuged at 15000 g for 30 min at 4oC, and the supernatant was 
poured off. In the next step, 500 µl of ice-cold 70% ethanol was added, and the solution 
was centrifuged at 15,000 g for 30 min at 4oC. The supernatant was poured off, the 
pellet was air dried completely, and finally it was reconstituted with 50 µl sterile distilled 
water.   
 
3.2.8.3.11. Transfection of HEK293A cells by recombinant adenovirus plasmid 
 
One day before transfection, HEK293A cells were seeded in 6 cm dishes with a density 
allowing to have 70% confluent cells the next day. After that, 4 µg of the linearized 
plasmid was used to transfect the cells using PolyFect reagent according to the 
manufacturer’s instruction. The transfected cells were maintained in the incubator for   
20 days, during which 0.5 ml of HEK293A low serum medium was added every 3rd day. 
 
3.2.8.3.12. Amplification of recombinant adenovirus by HEK293A cells 
 
After 20 days of transfection, the HEK293A cells were collected by scraping them off in 
the presence of the medium, and were thereafter exposed to three cycles of freezing 
and thawing using liquid nitrogen, followed by vigorous vortexing to disrupt the cells in 
order to release the virus particles. After that, the resulting suspension was centrifuged 
at 700 g for 5 min at room temperature to pellet the debris, and the supernatant was 
mixed with fresh HEK293A low serum medium, which was used to infect 70% confluent 
HEK293A cells cultured in 10 cm dish. When the cells started to detach (after about 
three days), they were collected and processed following the same steps mentioned 
above, and the obtained supernatant was used to infect 2x 15 cm dishes of HEK293A to 
start a new round of infection. In the next round, the supernatant of virus was used to 
infect 5x 15 cm dishes of HEK293A cells, and the supernatant obtained from these cells 
was used in the last round to infect 20x 15 cm dishes of HEK293A cells. At this point, 
when the cells start to round and slightly detach, they were flushed off the plate by their 
own medium, collected in 50 ml reaction tubes, centrifuged at 150 g for 10 min at room 
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temperature. Next, the pellet was resuspended in 50 ml PBS, centrifuged at 150 g for  
10 min at room temperature. The supernatant was aspired and the pellet was 
resuspended in 10 ml PBS. After that, the cell suspension was exposed to three cycles 
of freezing and thawing, followed by centrifugation at 700 g for 5 min at room 
temperature to pellet the cell debris.  
  
 
3.2.8.3.13. Purification of recombinant adenovirus 
 
In a 17 ml ultracentrifugation tube, 5 ml of light CsCl was added followed by the 
administration of 5 ml of heavy CsCl underneath the light CsCl, and the interphase was 
marked. After that, 5 ml of virus supernatant was added on top and the tubes were filled 
completely with PBS. Next, ultracentrifugation was performed using L8-70M device 
under vacuum, at 22000 g, 8oC for 24 hr. After that, the virus ring was aspired through 
the wall of the tube by a syringe. Then, the virus was purified by overnight dialysis: two 
times against 2000 ml PBS and one time against 2000 ml 1x virus storage buffer (VSB). 
Finally, the virus was stored in 45% glycerol in 1x VSB at -20oC.  
 
 
3.2.8.3.14. Cloning strategy  
 
Insertion of the TC tag in pcDNA3.1/Zeo(+) 5.0 kb vector 
 
First, the pcDNA3.1/Zeo 5.0 kb expression vector was linearized using KpnI and AflII 
restriction enzymes, and the linearized vector was purified as explained before. After 
that, the TC-tag oligoneocleotide, which has AflII and KpnI overhang, was ligated with 
the linearized vector, creating a TC-pcDNA3.1/zeo(+) vector. Next, DH10B bacteria were 
directly transformed with this vector using heat shock method, and minipreps were 
performed for the resulting bacterial colonies, using Exprep plasmid SV mini kit 
according to the manufacturer’s instructions. The positive colonies were determined by 
checking the yielded pcDNA with SmaI restriction enzyme, since the corresponding 
restriction site exists exclusively in the TC-tag. After that, midipreps were performed for 
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the positive colonies to get enough yield of the vector, using Exprep plasmid SV midi kit 
according to the manufacturer’s instructions.  
 
 
Insertion of CTGF gene downstream the TC-tag in the expression vector 
 
The CTGF PCR fragment with added restriction sites was processed with KpnI and XhoI 
restriction enzymes to create sticky ends. In parallel, the TC-pcDNA3.1/zeo(+) vector 
was linearized by the same restriction enzymes. Both CTGF gene and the linearized 
vector were isolated and purified as explained before. After that, the CTGF fragment was 
ligated downstream the TC-tag, creating TC-CTGF-pcDNA3.1/zeo(+) vector, which was 
used directly to transform DH10B bacteria by the heat shock method. Minipreps were 
performed for the resulting bacterial colonies, and the positive colonies were determined 
by checking the yielded pcDNA by KpnI, XhoI and PstI restriction enzymes (PstI can cut 
within two regions of CTGF gene). The presence of mutation was ruled out by 
sequencing the pcDNA of positive clones by Seqlab Company. Tsa201 cells were 
transfected with this construct using PolyFect reagent to validate the expression of TC-
CTGF fusion protein. 
 
 
Insertion of TC-CTGF-pcDNA3.1/zeo(+) vector in pShuttle-CMV vector 
 
TC-CTGF-pcDNA3.1/zeo(+) and pShuttle-CMV vectors were digested by PmeI and 
EcoRV restriction enzymes, respectively, to create blunt ends. After that, they were 
purified and ligated together as explained before creating TC-CTGF-pShuttle-CMV 
vector. Using heat shock method, DH10B bacteria were transformed by the resulting 
construct, followed by miniprep. Colonies having the correct orientation of ligation were 







Transformation of AdEasier cells with TC-CTGF-pShuttle-CMV vector to create 
adenovirus backbone for the expression of TC-CTGF 
 
TC-CTGF-pShuttle-CMV vector was linearized with PmeI restriction enzyme, and after 
that, it was purified as explained before. Next AdEasier cells were transformed by the 
linearized vector using Inoue protocol as described before, and miniprep was performed 
for the obtained colonies. Positive clones, which contain the TC-CTGF-pShuttle-CMV-




Transfection of HEK293A cells with TC-CTGF-AdEasy-1, and the production of high-titer 
recombinant adenovirus  
 
First the TC-CTGF-AdEasy-1 vector was linearized using PacI restriction enzyme. After 
that, the linearized vector was purified by isopropanol precipitation, and then it was used 
to transfect HEK293A cells. The cell lysate from these cells was used in repeated 
infection cycles, as described before, to infect increasing numbers of HEK293A cells. 
Finally, the recombinant adenovirus was isolated and purified as described before. 
  
 
3.2.9. Statistical analysis 
 
The data are shown as means ± standard error means (SEM). To test the differences 
between groups, one-way analysis of variance (ANOVA) test was performed. To further 
compare two groups, where the data in the same raw are matched, paired student’s t-
test was used, and otherwise unpaired student’s t-test was used. p-values less than or 









4.1. Role of Ca2+ in the regulation of CTGF  
 
4.1.1. Characterization of Ang II-induced Ca2+ transient in CF 
 
4.1.1.1. Ang II induces Ca2+ transient in both NRCF and NHCF-V 
 
First, the ability of NRCF to induce a Ca2+ transient in response to Ang II was 
investigated. To do so, NRCF were loaded with Fluo-8 Ca2+ sensitive fluorescent dye. 
While recording time lapse as one frame every 5 sec, 100 nM Ang II was applied at the 
20th sec, resulting in a sharp increase in the fluorescence intensity that could be 
detected in the subsequent frame (at 25th sec), which declined gradually until close to 
baseline level. This transient change in fluorescence intensity reflects a transient 
increase in the cytoplasmic Ca2+ concentration (Fig. 5A). The fluorescence intensity was 
measured by the arbitrary relative fluorescence unit (RFU) (Fig. 5B). In the next step, a 
concentration-response curve was performed using 4 different concentrations of Ang II 
(1, 10, 100 and 1000 nM). For each Ang II concentration, the means ± SEM of ΔRFUMax 
(maximal fluorescence  basal fluorescence) was used to calculate a concentration-
response curve. The calculated EC50 was 1.7 nM, and it was found that 100 nM Ang II 
was required to achieve a maximal response (Fig. 5C). In addition, the ability of normal 
human ventricular CF (NHCF-V) to generate a similar Ca2+ transient in response to    
Ang II was validated (Fig. 5D). In addition, Ang II was able to induce a concentration-





Figure 4: Ang II treatment induces rapid Ca2+ transient in CF
A) Cell images: NRCF were first loaded with the Ca2+ dye, then a time lapse recording was started, as one frame every 5 sec for 5 min,
with the first frame at 0 sec. In the first five frames, the cells looked dim, as the cytoplasmic Ca2+ concentration was low, which was
considered as base line (left image). Immediately after the 5th frame (20th sec), 100 nM Ang II was dispensed, as a result a strong increase
in the fluorescence was detected in the subsequent frame (right image), which reflects an increase in cytoplasmic Ca2+ concentration. The
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Figure 5: Induction of Ca2+ transients in NRCF and NHCF-V by different 
concentrations of Ang II 
NRCF and NHCF-V were loaded with the Ca2+ dye, then time lapse was recorded where 
Ang II was added at the 20th sec. A) Representative images for NRCF taken at 0 sec 
(baseline), after Ang II (100 nM) application at the 25th sec, and at the end of the time 
lapse at 300th sec B) The graph shows the analysis of the fluorescence, for control and 
100 nM Ang II-treated NRCF, over the time course of the experiment (n=4, for each n at 
least 3 wells/condition, 40-60 cells/well, means ± SEM). C) Ca2+ transients were 
analyzed in NRCF in the presence of 0, 1, 10, 100 and 1000 nM Ang II. The means ± 
SEM for ΔRFUMax from each Ang II concentration was used for the concentration-
response curve, where the calculated EC50 was 1.7 nM (n=3, for each n at least 3 
wells/condition, 40-60 cells/well, means ± SEM). D) Representative images for NHCF-V 
taken at 0 sec (baseline), after Ang II application at the 25th sec, and at the end of the 
time lapse at 300th sec E) The graph shows the analysis of the fluorescence for NHCF-V 
treated with two different concentrations of Ang II, as well as for a baseline (n=1, at least 
3 wells for each condition, 30-50 cells/well, means ± SEM, preliminary data). 
 
4.1.1.2. Ca2+ handling in NRCF is independent of the differentiation state  
 
To investigate whether the differentiation state of NRCF can influence the handling of 
Ca2+, the Ang II-induced Ca2+ transient (Ang II-CaT) was compared between passage 0 
(P0) and passage 1 (P1) NRCF. It was found that the basal fluorescence (basal Ca2+ 
level), the maximal fluorescence (peak level of Ca2+) and the area under the curve 





Figure 6: Comparison of the Ang II-CaT in P0 and P1 NRCF  
The Ang II-CaT was investigated in P0 and P1 NRCF, in the presence of 100 nM Ang II. 
The upper left graph demonstrates the trace of the detected fluorescence over 300 sec. 
The analysis of this graph is shown in the accompanying scatter plots. Upper right 
scatter plot illustrates the basal fluorescence level in P0 and P1 cells. Lower left scatter 
plot illustrates the maximal fluorescence intensity. Lower right scatter plot illustrates the 
area under the curve (AUC) (n=13, for each n at least 3 wells/condition, 40-60 cells/well, 
means ± SEM).  
 
4.1.1.3. AT1 receptor -PLC-β signaling cascade mediates the Ang II-CaT 
 
In order to verify that the observed Ca2+ transient in response to Ang II is mediated 
through the AT1 receptor-PLC-β canonical pathway, the Ang II-CaT was studied in 
NRCF treated with valsartan, which is a clinically used selective AT1 receptor blocker, or 
with the PLC-β inhibitor U73122 (122). U73343 (343) was used as a negative control for 
122. Both treatments significantly reduced the ΔRFUMax (Fig. 7A and B). To further 
determine whether the components of the signaling cascade are located in the caveolae, 
NRCF were treated with methyl-β-cyclodextrin (CDX), which disrupts caveolae by 
Ang II
Figure 5: Different passages of NRCF handle Ca2+ similarly 
P0 and P1 NRCF were first loaded with the Ca2+ dye, then live cell Ca2+ imaging
was performed, where 100 nM Ang II was added at the 20th sec. The upper left
graph demonstrates the trace of the detected fluorescence over 5 min. The analysis
of this graph is shown in the accompanying scatter plots. Upper right scatter plot
illustrates the basal fluorescence level in P0 and P1 cells. Lower left scatt r plot
illustrates the amplitude of the MFI. Lower right scatter plot illustrates the area under
























cholesterol depletion, before the Ang II-CaT was measured. This resulted in a significant 
reduction in the ΔRFUMax (Fig. 7C). The disruption of the caveolae was confirmed by 




Figure 7: Signaling cascade underlying the Ang II-CaT  
NRCF were treated with the inhibitors or the corresponding control conditions for 1 hr, 
before the Ang II-CaT was investigated. A) Effect of AT1 receptor blockade by 15 nM 
valsartan on the ΔRFUMax (n=7, for each n at least 3 wells/condition, 40-60 cells/well, 
means ± SEM, *p≤0.05) B) Effect of PLC-β inhibition by 1.5 µM 122 on the ΔRFUMax as 
compared to 1.5 µM of the negative control 343 (n=5, for each n at least 3 
wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05) C) Effect of caveolae disruption 
by 2.5 mM CDX on the ΔRFUMax (n=5, for each n at least 3 wells/condition, 40-60 
cells/well, means ± SEM, *p≤0.05) D) IF microscopy for caveolin-1 showing the 







Figure 6: Ang II induced Ca2+ transient in NRCF via AT1 receptor -PLC-β
signaling cascade
The cells were first incubated with the inhibi ors or the corresponding control co ditions 
for 1 hr, then loaded with the Ca2+ dye, followed by live cell Ca2+ imaging. A) Effect  of 
Ang II-type 1 receptor (AT1R) blockade, by 15 nM valsartan, on the MFI amplitude 
induced by 100 nM Ang II (N=7, mean  SEM, *p≤0.05). B) Effect of PLC-β inhibition, by 
1.5 µM U73122 (122), on the MFI amplitude induced by 100 nM Ang II as compared to 
the negative control U73343 (343) (N=5, mean  SEM *p≤0.05). C) Effect of the disruption 
of caveolae, by 2.5 mM methyl-β-cyclodextrin (CDX), on the MFI amplitu e induced by 
100 nM Ang II (N=5, mean  SEM, *p≤0.05). D) Immunofluorescence staining of caveolin-
1 showing the  disruption of caveolae by CDX. The antibody against caveolin-1 was 






































4.1.1.4. Intracellular Ca2+ stores are the major sources for the Ang II-CaT  
 
In order to investigate the involvement of the intracellular Ca2+ stores and the 
extracellular Ca2+ in the Ang II-CaT, the normal cell culture medium was replaced by 
Ca2+-free Tyrode’s solution during the recording of the time lapse, then Ang II was added 
in the absence of extracellular Ca2+ and the impact on the Ca2+ transient was studied. 
Finally, the extracellular Ca2+ level was restored. As shown in Fig. 8A, a first increase in 
cytoplasmic Ca2+ level was observed in response to the depletion of the extracellular 
Ca2+, then a second Ca2+ transient was induced in response to Ang II treatment, and 
finally a third Ca2+ transient was induced upon restoring the extracellular Ca2+ level. To 
further validate this finding, an experiment was performed, where first the cell culture 
medium was exchanged to Ca2+-free Tyrode’s solution, followed by restoration of the 
original extracellular Ca2+ level, and finally, the Ang II treatment was applied in the 
presence of extracellular Ca2+. Comparably, a first Ca2+ transient was induced in 
response to the depletion of the extracellular Ca2+, then a second Ca2+ transient 
occurred upon restoring the original extracellular Ca2+ level. Finally, Ang II treatment 
induced a Ca2+ transient. The amplitude of the transient was comparable to that 
observed in the absence of extracellular Ca2+ (Fig. 8B). As this data argued for a more 
prominent role for the intracellular Ca2+ stores in the Ca2+ transient, the effect of the 
intracellular Ca2+ store depletion by thapsigargin (TGN) was studied. As shown in Fig. 
8C, the ΔRFUMax was significantly reduced in TGN-treated NRCF. This pointed to a role 
for the inositol-triphosphate receptors (IP3Rs), therefore, the expression of these 
receptors by NRCF was checked by RT-PCR, which confirmed that all of the three 
isoforms of the IP3Rs could be could be detected (Fig. 8D). Next, the effect of IP3Rs 
blockade by xestospongin C (XeC) was investigated, which showed a significant 





Figure 8: Contribution of the intracellular Ca2+ stores to the Ang II-CaT 
A) The graphs show the background-subtracted fluorescence intensity (ΔRFU) over 
time. The cell culture medium was quickly replaced by Ca2+-free Tyrode’s solution at the 
20th sec. After that, 100 nM Ang II was added at the 180th sec. Finally, Ca2+ solution was 
added at the 360th sec to restore the original extracellular Ca2+ level (2 mM) (n=2, for 
each n at least 3 wells/condition, 40-60 cells/well, means ± SEM). B) The graphs show 
the ΔRFU over time. The cell culture medium was replaced by Ca2+-free Tyrode’s 
solution at the 20th sec. After that, Ca2+ was added at the 180th sec to restore the original 
extracellular Ca2+ level (2 mM). Finally, 100 nM Ang II was added at the 360th sec (n=2, 
Ca2+-free Tyrode
2 mM Ca2+






Figure 7: Intracellular Ca2+ stores are the major source for Ang II-induced Ca2+
transient in NRCF
A) The graphs show the change in fluorescence intensity over time. Left graph: While
ITPR1 ITPR2 ITPR3



































for each n at least 3 wells/condition, 40-60 cells/well, means ± SEM). C) Effect of pre-
depletion of intracellular Ca2+ stores by 3 µM TGN on the ΔRFUMax (n=4, for each n at 
least 3 wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05). D) DNA-agarose gel 
electrophoresis for the products of the RT-PCR showing the expression of IP3R1, IP3R2 
and IP3R3. The calculated length of the amplified DNA fragments is 259, 197 and 252 
base pairs, respectively. * is an unspecific band. E) Effect of IP3Rs blockade by 100 µM 
XeC on the ΔRFUMax (n=3, for each n at least 3 wells/condition, 40-60 cells/well, means 
± SEM, *p≤0.05). 
 
4.1.1.5. Blockade of TRPC3 channels enhances the ΔRFUMax of the Ang II-CaT 
 
To further investigate the impact of different Ca2+ sources on the regulation of the Ang II-
CaT, the effect of TRPC3 channels blockade by Pyr3 was investigated, which showed 
that the basal fluorescence intensity was reduced in Pyr3-treated NRCF compared to the 
control, but the maximal fluorescence was equal in both groups. This lead to an increase 
in the ΔRFUMax (Fig. 9A). The expression of TRPC3 channels by NRCF was confirmed 





Figure 9: Contribution of TRPC3 channels to the Ang II-CaT in NRCF 
A) The cells were treated with 3 µM Pyr3 for 1 hr before the Ang II-CaT was 
investigated. The graph shows the traces for the detected absolute fluorescence 
intensity in response to 100 nM Ang II in the presence and absence of Pyr3. The 
analysis of this graph is shown in the accompanying column graphs. The middle graph 
illustrates the basal level of absolute fluorescence intensity. The right graph shows the 
ΔRFUMax (n=7, for each n at least 3 wells/condition, 40-60 cells/well, means ± SEM, 
*p≤0.05). B) DNA-agarose gel electrophoresis for the products of the RT-PCR for 





Figure 8: Blockade of TRPC3 by Pyr3 reduces the basal fluorescence intensity, but
increases the MFI amplitude in response to Ang II in NRCF .
A) The cells were first incubated with 3 µM Pyr3 or the corresponding control conditions for 1 hr,
then loaded with the Ca2+ dye, followed by live cell Ca2+ imaging Left graph shows the traces
for the absolute fluorescence intensity in response to 100 nM Ang II, in the presence and
absence of 3 µM Pyr3. The analysis of this graph is shown in the accompanying column graphs.
The middle graph illustrates the basal level of absolute fluorescence intensity. The right graph
illustrates the MFI amplitude in response to Ang II (N=7, mean  SEM, *p≤0.05). B) The
expression of TRPC3 channels was verified by end-point PCR, using qPCR primers. The PCR




















4.1.1.6. TRPC3 channels and the intracellular Ca2+ stores play a role in the 
regulation of the Ang II-induced-Ca2+ oscillation 
 
Besides the induction of a Ca2+ transient by Ang II, spontaneous Ca2+ oscillation could 
be detected in NRCF (Fig. 10A). This phenomenon was evaluated by analyzing the 
percentages of the oscillating to the non-oscillating P0 and P1 cells, in the presence and 
absence of Ang II, which showed that following Ang II treatment, the proportion of Ca2+ 
oscillating cells was significantly increased, independent of the passage (Fig. 10B). 
However, this effect could not be prevented by valsartan (Fig. 10C). To study the 
sensitivity of the NRCF towards Ang II, the effect of 1 nM and 100 nM Ang II was 
compared. Interestingly, the submaximal concentration of 1 nM Ang II was sufficient to 
induce a maximal oscillation (Fig. 10D). After that, the contribution of the intracellular 
Ca2+ stores to the Ang II-induced Ca2+ oscillation was investigated by using TGN. As a 
result, the Ca2+ oscillation was completely inhibited (Fig. 10E). To investigate whether 
the TRPC3 channels are also involved in the regulation of Ca2+ oscillation, the influence 
of Pyr3 treatment was analyzed. Similar to TGN, treatment with Pyr3 significantly inhibit 
the effect of Ang II on Ca2+ oscillation (Fig. 10F). Finally, in a first experiment, it could be 





Figure 10: Investigation of Ca2+ oscillation in CF  
A) Representative series of images of NRCF showing Ca2+ oscillation over a time period 
of 50 sec. The graph shows the ΔRFU for the marked cells. B-F) For each field of the 



























NRCF was analyzed. B) Percentage of P0 and P1 NRCF that can spontaneously 
oscillate Ca2+ at the basal level and following 100 nM Ang II treatment (n=7, for each n at 
least 3 wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05 vs. basal P0, #p≤0.05 vs. 
basal P1). C) Effect of AT1 receptor blockade by 15 nM valsartan on the proportion of 
Ca2+ oscillating NRCF, with and without 100 nM Ang II (n=7, for each n at least 3 
wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05). D) Effect of 1 and 100 nM Ang 
II on the proportion of Ca2+ oscillating NRCF (n=3, for each n at least 3 wells/condition, 
40-60 cells/well, means ± SEM, *p≤0.05 vs. baseline). E) Effect of pre-depletion of 
intracellular Ca2+ stores by 3 µM TGN on the proportion of Ca2+ oscillating NRCF with 
and without 100 nM Ang II treatment (n=4, for each n at least 3 wells/condition, 40-60 
cells/well, means ± SEM, *p≤0.05). F) Effect of TRPC3 channel blockade by 3 µM Pyr3 
on the proportion of Ca2+ oscillating NRCF with and without 100 nM Ang II treatment 
(n=7, for each n at least 3 wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05). G) 
Investigating the occurrence of Ca2+ oscillation in NHCF-V. The graph shows the 
fluorescence traces for 6 individual cells treated with 100 nM Ang II. 
 
4.1.1.7. The NADPH oxidases (NOXs) and Rac1 GTPases are regulators of the 
Ang II-CaT in NRCF  
 
Higher magnification imaging revealed that the flux of Ca2+ is spatially regulated. In 
response to Ang II, there was a transient Ca2+ loading in the nucleus or the perinuclear 
space, and a transient Ca2+ loading inside the mitochondria in many cells (Fig. 11A). 
Several processes in the mitochondria are known to involve ROS generation, therefore, 
the effect of ROS on Ang II-mediated Ca2+ handling was investigated by targeting Rac1 
activation, which is among others a subunits of NOX1, 2, and 3, and by inhibition of 
NOX2 subunit gp91 phox activation. 
 
To determine whether the ROS producing NADPH-oxidases are involved in the 
regulation of Ca2+, the Ang II-CaT was investigated in NRCF treated with the Rac1 
activation inhibitor NSC23766 (NSC). By analyzing the change in fluorescence in the 
whole cells, a significant decrease in the ΔRFUMax was detected (Fig. 11B). Moreover, it 
was found that following Ang II treatment, around 30-40% of the control and NSC-
treated cells, showed Ca2+ loading in the mitochondria, which resolved over time in the 
control cells, so that after 170 sec only 10% of the cells showed mitochondrial Ca2+ 
69 
 
loading, while the mitochondrial Ca2+ loading was persistent in the NSC-treated cells. 
However, the loading of Ca2+ in the nuclei or the perinuclear space was not influenced 





























Figure 11: Investigation of the role of Rac1 in Ca2+ handling 
A) Representative image for the loading of Ca2+ in the mitochondria following 100 nM 
Ang II treatment. B) NRCF were incubated for 1 hr with 50 µM NSC, before the Ang II-
CaT was studied, where 100 nM Ang II was added at the 20th sec. The graph shows the 
effect of NSC treatment on the ΔRFUMax (n=7, for each n at least 3 wells/condition, 40-60 
cells/well, means ± SEM, *p≤0.05). C) Upper panel contains representative cell images 
showing the time-course for Ca2+ loading in the mitochondria and nuclei at 0, 25th and 
170th sec for control and NSC-treated cells. Lower graph shows the analysis of the 
proportion of cells with mitochondrial Ca2+ loading at the defined time points (n=7, for 
each n at least 3 wells/condition, 40-60 cells/well, means ± SEM, # vs. control + Ang II at 
170th sec, p≤0.05). 
 
To further investigate the role of ROS in the regulation of Ca2+ handling in NRCF, a 
gp91-ds-tat peptide was used to specifically inhibit the association of gp91phox with 
p47phox, thus preventing the assembly of NOX2 subunits. A scrambled peptide with ds-
tat motif (Scr) was used as a negative control. Similar to NSC treatment, the gp91-ds-tat 
peptide decreased the ΔRFUMax significantly by approximately 40% (Fig. 12A). However, 
in contrast to the inhibition of the Rac activation, the duration of Ca2+ loading in the 































Figure 12: Investigation of the role of NOX2 in Ca2+ handling  
NRCF were incubated for 1 hr with 5 µM gp91-ds-tat or Scr before the Ang II-CaT was 
studied. A) Effect of gp91-ds-tat treatment on the ΔRFUMax (n=3, for each n at least 3 
wells/condition, 40-60 cells/well, means ± SEM, *p≤0.05). B) Upper panel contains 
representative cell images showing the time-course for Ca2+ loading in the mitochondria 
and nuclei at 0, 25th and 170th sec for the Scr and gp91-ds-tat-treated cells. Lower graph 
shows the analysis of the proportion of the cells with mitochondrial Ca2+ loading at the 




4.1.2. Ca2+ controls the expression and secretion of CTGF  
 
4.1.2.1. Chelation of intracellular Ca2+ by BAPTA-AM affects the basal and 
induced levels of CTGF expression and secretion 
 
After the characterization of the Ang II-CaT in NRCF, its impact on CTGF expression 
and secretion was studied. To do so, first a control experiment was performed in which 
the NRCF were treated with BAPTA-AM and the effectiveness of Ca2+ chelation was 
studied by Ca2+ imaging after Ang II application. Compared to control conditions, 
BAPTA-AM significantly reduced the ΔRFUMax by 70% reflecting the successful chelation 
of free Ca2+ in these cells (Fig. 13A). In next step, the impact of BAPTA-AM on the 
transcription of the immediate-early gene CTGF was analyzed under basal conditions 
and 2 hr after Ang II application, which induced the transcription of CTGF by 3-folds. In 
the presence of BAPTA-AM, however, this increase was completely suppressed and the 
basal CTGF gene transcription was also significantly reduced (Fig. 13B). To verify this 
finding on protein level, the effect of BAPTA-AM was investigated on the regulation of 
CTGF protein over 24 hr under basal conditions and after Ang II treatment. Ang II 
treatment alone significantly increased the intracellular CTGF by 0.5-fold and the 
secreted CTGF by 3.5 fold, however, in the presence of BAPTA-AM, the effect of Ang II 






Figure 13: Investigation of the general role of Ca2+ in the regulation of CTGF 
expression and secretion 
A) The graph shows ΔRFUMax for the Ang II-CaT, where NRCF were treated for 1 hr with 
7 µM BAPTA-AM or the corresponding control condition before 100 nM Ang II was 
applied (n=3, for each n at least 3 wells/condition, 40-60 cells/well, means ± SEM, 
*p≤0.05). For the experiments shown in B and C, NRCF were treated for 1 hr with 7 µM 
BAPTA-AM or the corresponding control condition before 100 nM Ang II was added. For 
the qPCR data shown in B, the RNA was isolated 2 hr after Ang II treatment, whereas 
for the immunoblotting data shown in C the cell lysates and the conditioned media were 
collected 24 hr after Ang II treatment. B) Effect of BAPTA-AM treatment on CTGF gene 
transcription. The data were normalized to PBGD, and the change in gene transcription 
was calculated relative to the control (n=3, means ± SEM, * and #p≤0.05, * vs. control, # 
vs. Ang II). C) Effect of BAPTA-AM treatment on the intracellular and secreted CTGF 
protein levels under basal and Ang II effects. Left are representative immunoblots, right 
are the relative quantification of the intracellular and secreted CTGF shown. The data 
Figure 12: Chelation of cytoplasmic Ca2+ inhibits CTGF expression and
secretion
Live cell Ca2+ imaging was performed in NRCF pre-incubated for 1 hr with 7 µM A)
BAPTA-AM, where 100 nM Ang II was added at the 20th sec. The graph shows the
change in the amplitude of MFI in response to Ang II, in control and BAPTA-AM-
treated cells (N=3, mean  SEM, *p≤0.05). B and C) NRCF were pre-incubated for 1
hr with 7 µM BAPTA-AM or the corresponding control conditions, after that, they were
treated with 100 nM Ang II. For the qPCR data shown in B,. the RNA was isolated 2 hr
following Ang II tr tment, whereas for the immunoblotting data shown in C, the cell
lysates and the conditioned media were collected 24 hr following Ang II treatment. B)
Effect of BAPTA-AM treatment on CTGF gene transcription. The change was
calculated relative to the control, and normalized to PBGD (N=3, means  SEM, * and
# p≤0.05. * vs. control, # vs. Ang II). C) Effect of BAPTA-AM treatment on the
intracellular and secreted CTGF levels, under basal and Ang II effects. Left are
representative immunoblots. Right graphs show the relative quantification for
intrac llular and secreted CTGF. The data were normalized to β- ctin, and the change
in CTGF level was calculated relative to the control (N=5, means  SEM, * and #





























were normalized to β-actin, and the change in CTGF level was calculated relative to the 
control (n=5, means ± SEM, * and #p≤0.05, * vs. control, #vs. Ang II).  
 
In addition, fluorescence microscopy was performed for NRCF treated for 24 hr with 
BAPTA-AM to analyze its effect on CTGF localization and the cytoskeleton´s integrity 
and organization. As shown in Fig. 14, there was no clear effect of the BAPTA-AM 
treatment on the CTGF localization in the Golgi apparatus, or on the integrity and 







Figure 14: Fluorescence microscopy of NRCF treated for 24 hr with BAPTA-AM  
The cells were incubated with 7 µM BAPTA-AM for 24 hr, after which they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (red). The actin filaments were stained with FITC-
phalloidin (green), the membranous structures, including the Golgi apparatus, were 
stained with Alexa-fluor 488 conjugated-WGA (green), and the nuclei were stained with 
DAPI (blue).  
 
 
As shown by the qPCR and immunoblotting data, the effect of BAPTA-AM was more 
pronounced in the qPCR data, where the cells were treated with BAPTA-AM for only      
3 hr. Since BAPTA-AM is known to be unstable for a long time in cell culture, 
fluorescence microscopy was performed for NRCF treated with BAPTA-AM for 3 hr to 
explore the impact on the localization of CTGF and on the status of the cytoskeleton. As 
shown in Fig. 15, BAPTA-AM treatment disrupted of the Golgi apparatus into 
membranous structures containing CTGF. There was also a disruption of actin filaments 








Figure 15: Fluorescence microscopy of NRCF treated for 3 hr with BAPTA-AM  
The cells were incubated with 7 µM BAPTA-AM for 3 hr, after which they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (red). The actin filaments were stained with FITC-
phalloidin (green), the membranous structures, including the Golgi apparatus, were 
stained with Alexa-fluor 488 conjugated-WGA (green), and the nuclei were stained with 





4.1.2.2. Depletion of intracellular Ca2+ by TGN affects mainly CTGF secretion 
 
After the effect of Ca2+ chelation was investigated, further experiments were performed 
to determine the effect of the intracellular Ca2+ depletion by TGN on the regulation of 
CTGF by Ang II, which showed that in the presence of TGN the stimulatory effect of  
Ang II on CTGF secretion was completely suppressed, but there was no effect on the 
basal level of secretion. Also, there was no significant effect for TGN on the intracellular 
CTGF (Fig. 16).  
 
 
Figure 16: Investigating the effect of intracellular Ca2+ depletion by TGN on CTGF 
regulation 
NRCF were treated for 1 hr with 3 µM TGN or the corresponding control condition, 
before they were treated with 100 nM Ang II. After 24 hr, the cell lysates and the 
conditioned media were collected. Upper panel showing representative immunoblots. 
The graphs below show the relative quantification of the intracellular and secreted 
CTGF. The data were normalized to β-actin, and the change in CTGF level was 
Figure 14: Depletion of intracellular Ca2+ inhibits CTGF secretion
NRCF were pre-incubated for 1 hr with 3 µM TGN or the corresponding control conditions,
after that, they were treated with 100 nM Ang II. 24 hr later, the cell lysates and the
conditioned media were collected. Upper panel are representative immunoblots. The
graphs below show the relative quantification for intracellular and secreted CTGF. The
data were normalized to β-actin, and the change in CTGF level was calculated relative to













calculated relative to the control (n=4, means ± SEM, * and #p≤0.05, * vs. control, # vs. 
Ang II). 
 
Moreover, fluorescence microscopy was performed for NRCF treated with TGN to 
analyze its effect on CTGF localization and the cytoskeleton’s integrity and organization, 
which revealed that TGN treatment disrupted the morphology of Golgi apparatus, while 
CTGF protein was dispersed throughout the cytosol. Moreover, TGN treatment affected 






Figure 17: Fluorescence microscopy of TGN-treated NRCF  
The cells were incubated for 24 hr with 3 µM TGN, after which they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The actin filaments were stained with TRITC-
phalloidin (red), the membranous structures, including the Golgi apparatus, were stained 




4.1.2.3. Blockade of IP3Rs by XeC inhibits CTGF secretion 
 
After it was found that the depletion of intracellular Ca2+ stores suppresses the secretion 
of CTGF, the effect of IP3Rs blockade by XeC was evaluated on the regulation of CTGF 
protein in the presence and absence of Ang II. Immunoblotting data analysis revealed 
that XeC significantly reduced the basal and induced levels of CTGF secretion, without 

















Figure 18: Evaluating the effect of IP3R blockade by XeC on CTGF regulation 
NRCF were treated for 1 hr with 1.4 µM TGN or the corresponding control condition, 
before they were treated with 100 nM Ang II. After 24 hr, the cell lysates and the 
conditioned media were collected. Upper panel showing representative immunoblots. 
The graphs below show the relative quantification of the intracellular and secreted 
CTGF. The data were normalized to β-actin, and the change in CTGF level was 
calculated relative to the control (n=5, means ± SEM, * and #p≤0.05, * vs. control, # vs. 
Ang II). 
 
IF microscopy was also performed to determine the effect of XeC treatment on the 
localization of CTGF as well as on the integrity and organization of actin filaments and 
microtubules. As shown in Fig. 19, XeC partially disrupted the morphology of Golgi 
apparatus, and the cytoplasm of XeC-treated cells seemed to contain more CTGF 
vesicles. In the same time, no effect could be detected on the status of actin filaments 







Figure 19: Fluorescence microscopy of XeC-treated NRCF  
The cells were incubated for 24 hr with 1.4 µM TGN, after which they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The actin filaments were stained with TRITC-
phalloidin (red), the membranous structures, including the Golgi apparatus, were stained 





4.1.2.4. Blockade of TRPC3 channels induces CTGF secretion, without 
influencing the expression 
 
As shown in Fig. 9A and Fig. 10F, TRPC3 channels were found to play a role in the 
regulation of the Ang II-CaT and the Ang II-induced Ca2+ oscillation. The next step was 
to determine whether TRPC3 channels can therefore play a role in the regulation of 
CTGF expression by Ang II. To do so, the effect of Pyr3 on the transcription of the 
immediate-early gene CTGF was analyzed under basal conditions and 2 hr following 
Ang II application, which revealed that treatment with Pyr3 had no effect on the basal or 
induced levels of CTGF gene transcription (Fig. 20A). In addition, immunoblotting 
analysis was performed to evaluate the effect of Pyr3 on the intracellular and secreted 
CTGF protein under basal and Ang II treatment, which showed that treatment with Pyr3 
had no effect on the basal levels of intracellular and secreted CTGF, but upon Ang II 
treatment, the intracellular level of CTGF was significantly reduced while the secreted 





Figure 16: The blockade of TRPC3 channels induced CTGF secretion
NRCF were pre-incubated for 1 hr with 3 µM Pyr3 or the corresponding control conditions,
after that, they were treated with 100 nM Ang II. For the immunoblotting data shown in A,
the cell lysates and the conditioned media were collected 24 hr following Ang II treatment,
whereas for the qPCR data shown in B,. the RNA was isolated 2 hr following Ang II
treatment. A) Effect of Pyr3 treatment on the intracellular and secreted CTGF levels,
under basal and Ang II effects. Upper panel are representative immunoblots, the graphs
below show the relative quantification for intracellular and secreted CTGF. The data were
normalized to β-actin, and the change in CTGF level was calculated relative to the control
(N=8, means  SEM, * and # p≤0.05. * vs. control, # vs. Ang II).B) Effect of Pyr3 treatment
on CTGF gene transcription. The change was calculated relative to the control, and

















Figure 20: Investigating the effect of TRPC3 blockade on CTGF regulation 
NRCF were treated for 1 hr with 3 µM Pyr3 or the corresponding control condition, 
before 100 nM Ang II was added. For the qPCR data shown in A, the RNA was isolated 
2 hr following Ang II treatment, whereas for the immunoblotting data shown in B, the cell 
lysates and the conditioned media were collected 24 hr after Ang II treatment. A) Effect 
of Pyr3 treatment on CTGF gene transcription under basal and Ang II effects. The data 
were normalized to PBGD, and the change in gene transcription was calculated relative 
to the control (n=3, means ± SEM, * and #p≤0.05, * vs. control, # vs. Ang II). B) Effect of 
Pyr3 treatment on the intracellular and secreted CTGF levels, under basal and Ang II 
effects. Upper panel shows representative immunoblots, the graphs below show the 
relative quantification for the intracellular and secreted CTGF. The data were normalized 
to β-actin, and the change in CTGF level was calculated relative to the control (n=8, 
means ± SEM, * and #p≤0.05, * vs. control, # vs. Ang II).  
 
Besides, NRCF treated with Pyr3 were examined by fluorescence microscopy to 
determine the effect of Pyr3 on CTGF localization and the cytoskeleton’s integrity and 
organization. As shown in Fig. 21, there was no clear effect for Pyr3 treatment on CTGF 
localization in Golgi apparatus, or on the integrity and organization of the actin filaments 






Figure 21: Fluorescence microscopy for NRCF treated with Pyr3  
The cells were incubated for 24 hr with 3 µM Pyr3. After that, they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (red). The actin filaments were stained with FITC-
phalloidin (green), the membranous structures, including Golgi apparatus, were stained 





4.1.2.5. Inhibition of NOX2 subunits assembly has no impact on the regulation 
of CTGF 
 
After it has been shown that the inhibition of NOX2 subunits assembly by gp91-ds-tat 
interfered with the regulation of Ca2+ handling in NRCF, the effect of gp91-ds-tat 
treatment on the regulation of CTGF was investigated by immunoblotting, which showed 
no impact for gp91-ds-tat treatment on the basal or induced levels of the intracellular or 




Figure 22: Evaluation of the effect of NOX2 inhibition by gp91-ds-tat on CTGF 
regulation 
NRCF were incubated for 1 hr with 5 µM Scr (negative control) or 5 µM gp91-ds.tat, 
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Figure 18: The blockade of NOX2 subunits assembly has no impact on CTGF
regulation
NRCF were pre-incubated for 1 hr with 5 µM Scr (negative control) or 5 µM gp91-ds.tat,
after that, they were treated with 100 nM Ang II. After 24 hr, the cell lysates and the
conditioned media were collected. Upper panel are representative immunoblots. Lower
graphs show the relative quantification for intracellular and secreted CTGF. The data were
normalized to β-actin, and the change in CTGF level was calculated relative to the control
(N=3, means  SEM, * and # p≤0.05. * vs. control, # vs. Ang II).
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were collected. Upper panel are representative immunoblots. Lower graphs show the 
relative quantification for the intracellular and secreted CTGF. The data were normalized 
to β-actin, and the change in CTGF level was calculated relative to the Scr (n=3, means 
± SEM, *p≤0.05, * vs. Scr).  
 
 
4.1.3. Determination of downstream targets for Ca2+ that mediate CTGF regulation 
 
4.1.3.1. Calcineurin and PKC oppositely regulate CTGF expression  
 
After it had been established that Ca2+ plays a role in the regulation of CTGF, the next 
step was to determine downstream targets through which Ca2+ can influence CTGF 
expression and secretion. Therefore, PKC (Ca2+-dependent kinases) and calcineurin 
(Ca2+-dependent phosphatase) were investigated.  
In order to confirm that both PKC and calcineurin are located downstream Ca2+ and have 
no impact on the handling of Ca2+ itself, Ang II-CaT was investigated in the presence of 
the PKC inhibitor Go 6983 and the calcineurin inhibitor CsA. As shown in Fig. 23A and 
B, there was no effect for either of these two inhibitors on the ΔRFUMax. In addition, the 
impact of Go 6983, CsA and a combination of both on the transcription of the immediate-
early gene CTGF was analyzed under basal conditions and 2 hr after Ang II application, 
which showed that Go 6983 significantly reduced the basal and induced levels of CTGF 
gene transcription. In contrast, CsA significantly increased the basal and induced levels 
of CTGF gene transcription. However, when a combination of both treatments was 
applied, CsA was no longer able to enhance CTGF gene transcription (Fig. 23C). 
Moreover, the effect of Go 6983 was investigated on the regulation of CTGF at the 
protein level by immunoblotting, which demonstrated that treatment with Go 6983 
significantly reduced the basal and induced levels of intracellular and secreted CTGF 
(Fig. 23D). In parallel, the effect of CsA on the regulation of CTGF at the protein level 
was also evaluated by immunoblotting analysis, which revealed that treatment with CsA 
significantly reduced the basal and induced levels of the intracellular CTGF, without 







Figure 23: Investigating the role of PKC and calcineurin in CTGF regulation 
A) NRCF were incubated with 6 µM Go 6983 before the Ang II-CaT was investigated. 
The graph shows the effect of Go 6983 on the ΔRFUMax (n=3, for each n at least 3 
wells/condition, 40-60 cells/well, means ± SEM *p≤0.05). B) NRCF were incubated with 
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20 nM CsA before the Ang II-CaT was investigated. The graph shows the effect of CsA 
on the ΔRFUMax (n=3, for each n at least 3 wells/condition, 40-60 cells/well, means ± 
SEM, *p≤0.05). C) NRCF were incubated with 6 µM Go 6983, 20 nM CsA or a 
combination of both for 1 hr, before 100 nM Ang II was added. The RNA was isolated    
2 hr following Ang II treatment and was used to analyze the change in CTGF gene 
transcription by qPCR. The data were normalized to PBGD, and the change in gene 
transcription was calculated relative to the control (n=3, means ± SEM, *p≤0.05 vs. 
control, #p≤0.05 vs. Ang II). D) NRCF were treated for 1 hr with 6 µM Go 6983 or the 
corresponding control condition, after that 100 nM Ang II was added. The cell lysates 
and the conditioned media were collected 24 hr later. Left are representative 
immunoblots shown. The graphs on the right show the relative quantification for the 
intracellular and secreted CTGF. The data were normalized to β-actin, and the change in 
CTGF level was calculated relative to the control (n=4, means ± SEM, *p≤0.05 vs. 
control, #p≤0.05 vs. Ang II). E) NRCF were treated for 1 hr with 20 nM CsA or the 
corresponding control conditions, after that 100 nM Ang II was added. The cell lysates 
and the conditioned media were collected 24 hr later. Left are representative 
immunoblots shown. The graphs on the right show the relative quantification for the 
intracellular and secreted CTGF. The data were normalized to β-actin, and the change in 
CTGF level was calculated relative to the control (n=4, means ± SEM, *p≤0.05 vs. 
control, #p≤0.05 vs. Ang II).  
 
The effect of 24 hr-treatment with Go 6983 on CTGF localization and the cytoskeleton’s 
integrity and organization was determined by fluorescence microscopy, which revealed 
that Go 6983 treatment resulted in the collapse and condensation of the Golgi apparatus 
and the disruption of the actin filaments. CTGF remained localized in the Golgi 





Figure 24: Fluorescence microscopy for NRCF treated for 24 hr with Go 6983  
The cells were incubated for 24 hr with 6 µM Go 6983. After that, they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The actin filaments were stained with TRITC-
phalloidin (red), the membranous structures, including the Golgi apparatus, were stained 
with Alexa-fluor 488 conjugated-WGA (green), and the nuclei were stained with DAPI 
(blue).  
 
In order to determine, whether 3 hr-treatment with Go 6983 can also cause structural 
changes in NRCF, fluorescence microscopy was performed for this purpose, which 
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revealed that the disruption of the Golgi apparatus can already be observed within this 





Figure 25: Fluorescence microscopy for NRCF treated for 3 hr with Go 6983  
The cells were incubated for 3 hr with 6 µM Go 6983. After that, they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The actin filaments were stained with TRITC-
phalloidin (red), the membranous structures, including the Golgi apparatus, were stained 
91 
 
with Alexa-fluor 488 conjugated-WGA (green), and the nuclei were stained with DAPI 
(blue).  
 
The effect of CsA treatment on CTGF localization and the cytoskeleton’s status was also 
investigated by fluorescence microscopy. As shown in Fig. 26, the complexities of the 
cell membrane in the CsA-treated cells were lost, and the morphology of the Golgi 
apparatus became unclear, but it was not disrupted. However, there was no clear effect 







Figure 26: Fluorescence microscopy for CsA-treated NRCF  
The cells were incubated for 24 hr with 20 nM CsA. After that, they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The actin filaments were stained with TRITC-
phalloidin (red), the membranous structures, including the Golgi apparatus, were stained 




4.1.3.2. Ca2+ regulates CTGF independently of ERK1/2 or Ca2+/calmodulin-
dependent protein kinase IIδ (CaMKIIδ) signaling 
 
Other downstream targets of Ca2+, which could be involved in the regulation of CTGF, 
were also investigated including ERK1/2 and CaMKIIδ. To do so, the phosphorylation of 
ERK1/2 by Ang II was investigated in NRCF in the presence and absence of BAPTA-
AM, which demonstrated that Ang II-induced ERK1/2 phosphorylation was not 
influenced by intracellular Ca2+ chelation (Fig. 27A). In addition, the effect of Ang II on 
CaMKII phosphorylation was investigated in the presence of the CaMKII phosphorylation 
inhibitor Kn-93 and its negative control Kn-92. As shown in Fig. 27B, Ang II did not 
induce CaMKII phosphorylation (preliminary data). Moreover, CaMKII inhibition did not 






Figure 27: Verification of the role of ERK1/2 and CaMKII in the Ca2+-dependent  
Ang II signaling 
A) NRCF were incubated for 1 hr with 7 µM BAPTA-AM or the corresponding control 
conditions before treatment with 100 nM Ang II. The cell lysates were collected 5 min 
thereafter. Left are representative immunoblots of phospho and total ERK1/2 proteins. 
Right graph shows the analysis of the change in ERK1/2 phosphorylation. The data were 
normalized to total ERK1/2, and the change in phosphorylation was calculated relative to 
the control (n=4, means ± SEM, * p≤0.05 vs. control). B) NRCF were incubated for 1 hr 
with 2 µM Kn-92 or Kn-93, before treatment with 100 nM Ang II. The cell lysates were 
collected 5 min thereafter. Representative immunoblots for phospho-and total CaMKII 
are shown (preliminary data). C) NRCF were incubated with 2 µM Kn-93 or 2 µM of the 
negative control Kn-92 before the Ang II-CaT was investigated. The graph shows the 
effect of CaMKII phosphorylation inhibition on the ΔRFUMax (n=1, 3 wells/condition, 40-
60 cells/well, means (of replicates) ± SEM, preliminary data). 

























4.1.3.3. Ca2+, PKC and Rac1 are involved in CTGF regulation in NHCF-V 
 
To validate the role of Ca2+, PKC and Rac1 in the regulation of CTGF in human cardiac 
fibroblasts, NHCF-V were incubated with BAPTA-AM, Go 6983 and NSC before they 
were treated with Ang II. As shown in the immunoblot in Fig. 28, BAPTA-AM was at least 
able to inhibit the secretion of CTGF, Go 6983 reduced both the intracellular and 
secreted CTGF, and NSC reduced mainly the intracellular CTGF. This experiment was 
performed only once. 
 
 
Figure 28: Validating the role of Ca2+, PKC and Rac1 in the regulation of CTGF in 
NHCF-V 
NHCF-V were incubated for 1 hr with 7 µM BAPTA-AM, 6 µM Go 6983, 50 µM NSC or 
the corresponding control condition before they were treated with 100 nM Ang II. The 
cell lysates and the conditioned media were collected 24 hr following Ang II treatment. 
Shown are immunoblots of the intracellular and secreted CTGF. β-actin is shown as a 
















Figure 23: Ca2+, PKC and Rac1 are involved in the regulation of
CTGF in NHCF-V.
NHCF-V were pre-incubated for 1 hr with 7 µM BAPTA-AM, 6 µM Go
6983, 50 µM NSC 23766, 20 nM CsA or the corresponding control
conditions, after that, they were treated with 100 nM Ang II. The cell
lysates and the conditioned media were collected 24 hr following Ang II
treatment. Shown are immunoblots for the intracellular and secreted
CTGF. β-actin is shown as a loading control.
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4.2. Role of the cytoskeleton in CTGF regulation 
 
4.2.1. Role of the actin filaments in CTGF regulation 
 
The role of the actin filaments in the regulation of CTGF in NRCF was investigated using 
latrunculin-A (LAT-A), which is a natural compound known to disrupt actin filaments. 
First of all, fluorescence microscopy was performed to confirm the effect of LAT-A on the 
actin filaments, and to study the consequences of the disruption of the actin filaments on 
CTGF localization. Cell imaging by fluorescence microscopy clearly showed that the 
actin filaments were disrupted by LAT-A treatment, and that the Golgi apparatus became 




Figure 29: Fluorescence microscopy of NRCF treated with LAT-A  
NRCF were incubated for 24 hr with 8.5 ng/ml LAT-A. After that, they were fixed, 
permeabilized and incubated with a blocking solution. CTGF was detected by IF staining 
(red), the actin filaments were stained with FITC-phalloidin (green), and the nuclei were 




To rule out the possibility that LAT-A might influence the microtubules, co-fluorescence 
staining for actin filaments and microtubules was performed in LAT-A-treated cells, 





Figure 30: Fluorescence microscopy of the effect of LAT-A on microtubules  
NRCF were incubated for 24 hr with 8.5 ng/ml LAT-A. After that, they were fixed, 
permeabilized and incubated with a blocking solution. The actin filaments were stained 
with TRITC-phalloidin (red), α-tubulin was detected by IF staining (green) and the nuclei 
were stained with DAPI (blue). 
 
In the next step, the consequences of the actin filaments disruption by LAT-A on the 
regulation of CTGF by Ang II was investigated at the level of gene expression. The 
analysis of the qPCR data showed that treatment with LAT-A significantly inhibited the 
basal and Ang II-induced levels of CTGF gene transcription (Fig. 31A). In the same time, 
immunoblotting analysis was performed to evaluate CTGF regulation at the protein level, 
which showed that upon disruption of the actin filaments, Ang II was no longer able to 
increase the intracellular or the secreted CTGF. Also, the basal level of intracellular 
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Figure 31: Investigating the effects of the actin filaments disruption on CTGF 
regulation  
NRCF were incubated for 1 hr with 8.5 ng/ml, before they were treated with 100 nM Ang 
II. For the qPCR data shown in A, the RNA was isolated 2 hr following Ang II treatment, 
whereas for the immunoblotting data shown in B, the cell lysates and the conditioned 
media were collected 24 hr following Ang II treatment. A) Effect of LAT-A treatment on 
CTGF gene transcription under basal and Ang II effect. The data were normalized to 
PBGD, and the change in gene transcription was calculated relative to the control (n=3, 
means ± SEM, * and #p≤0.05, * vs. control, # vs. Ang II). B) Effect of LAT-A treatment on 
the intracellular and secreted CTGF levels, under basal and Ang II effects. Upper panel 
demonstrates representative immunoblots. The graphs below show the relative 
quantification of the intracellular and secreted CTGF. The data were normalized to α-
tubulin, and the change in CTGF level was calculated relative to the control (n=5, means 
± SEM, * and #p≤0.05, * vs. control, # vs. Ang II).  
Figure 26: Disruption of actin filaments inhibits CTGF expression and secretion.
A) NRCF were pre-incubated for 1 hr with 8.5 ng/ml. After that, they were treated with
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4.2.2. Role of the microtubules in the regulation of CTGF  
 
The role of microtubules in the regulation of CTGF was verified in NRCF using 
colchicine, which is a clinically used drug that disrupts microtubules. In the first step, 
fluorescence microscopy was performed to confirm the effect of colchicine on the 
microtubules, and to study the consequences on the localization of CTGF. As shown in 
Fig. 32, the microtubules were depolymerised and randomly dispersed throughout the 
cytosol in the form of tubulin aggregates. In addition, the Golgi apparatus, where CTGF 






Figure 32: Fluorescence microscopy for NRCF treated with colchicine  
The cells were incubated for 24 hr with 5 µg/ml colchicine. After that, they were fixed, 
permeabilized and incubated with a blocking solution. IF staining was performed to 
detect CTGF (red) and α-tubulin (green). The membranous structures, including the 
Golgi apparatus, were stained with Alexa-fluor 488 conjugated-WGA (green), and the 
nuclei were stained with DAPI (blue).  
 
In the next step, the consequence of the microtubules disruption was investigated on the 
regulation of CTGF gene transcription at the basal level and 2 hr following Ang II 
treatment. The analysis of the qPCR data showed that treatment with colchicine 
significantly enhanced the level of CTGF gene transcription, which could not be 
increased further by Ang II (Fig. 33A). The successful disruption of microtubules within   
2 hr was confirmed by immunofluorescence microscopy of α-tubulin (Fig. 33B). Further 
biochemical analysis, by immunoblotting of protein samples from cells treated over 24 hr 
with colchicine in the presence and absence of Ang II, showed that upon disruption of 
the microtubules, the intracellular and secreted levels of CTGF were significantly 
increased, and that Ang II was no longer able to enhance it further. In addition, the level 
of α-tubulin was significantly reduced (Fig. 33C). In addition, by using sirius red-based 
colorimetric microassay it was found that colchicine treatment had no effect on the 






Figure 33: Disruption of microtubules by colchicine significantly induces CTGF 
expression and secretion 
A) NRCF were treated for 1 hr with 5 µg/ml colchicine or the corresponding control 
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2 hr colchicine treatment
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for the analysis of CTGF gene transcription by qPCR. The data were normalized to 
PBGD, and the change in gene transcription was calculated relative to the control (n=3, 
means ± SEM, * and #p≤0.05, * vs. control, # vs. Ang II). B) IF staining for the detection 
of α-tubulin in NRCF treated with 5 µg/ml colchicine over 2 hr.  C) NRCF were treated for 
1 hr with two different concentrations of colchicine (1.3, 5 µg/ml) or the corresponding 
control conditions, before they were treated with 100 nM Ang II. The cell lysates and the 
conditioned media were collected 24 hr following Ang II treatment. Representative 
immunoblots are presented along with graphs showing the relative quantification for α-
tubulin and the intracellular and secreted CTGF. The data were normalized to β-actin, 
and the change in CTGF and α-tubulin levels were calculated relative to the control (n=6, 
means ± SEM, * and #p≤0.05, * vs. control, # vs. Ang II). D) NRCF were treated overnight 
with two different concentrations of colchicine (1.3, 5 µg/ml), 10% FCS (positive control) 
or the corresponding negative control condition. After that sirius red-based colorimetric 
microassay was performed. The graph shows the relative quantification for the deposited 
collagen (preliminary data, n=2, 6 replicates, means ± SEM).  
 
 
4.3. Prospects for studying CTGF by live cell imaging using Ad.TC-CTGF 
 
After construction of the adenovirus encoding the TC-CTGF fusion protein (Ad.TC-
CTGF), the functionality of the virus was evaluated in NRCF. First, IF microscopy was 
performed for NRCF infected with Ad.TC-CTGF or the control virus Ad.EGFP, which 
showed that in case of Ad.TC-CTGF infection EGFP-positive cells displayed a strong 
expression of CTGF (Fig. 34A). The next step was to confirm that the over-expressed 
CTGF was tagged by TC, and that it can be secreted. To do so, NRCF were infected 
with Ad.EGFP, Ad.TC-CTGF and an adenovirus over-expressing hemagglutinin (HA) 
tagged-CTGF (Ad.HA-CTGF), which was considered as a positive control. As shown in 
the immunoblot in Fig. 34B, single bands of CTGF were observed in the lysate and 
conditioned medium of the Ad.EGFP-infected cells, whereas, double bands were 
observed in the cell lysate and conditioned medium of the Ad.HA-CTGF-infected cells, 
but for the Ad.TC-CTGF-infected NRCF, double bands of CTGF were observed in the 
cell lysate only, while there was only a single band of CTGF in the medium. 
From this immunoblot, it was concluded that the TC-CTGF could be over-expressed in 
NRCF, but during certain stages of processing the TC- tag was cleaved, and only the 
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untagged CTGF could be secreted, which explains why greater amounts of the 
endogenous CTGF could be detected in the cell lysate and conditioned medium. 
Regarding the positive control virus Ad.HA-CTGF, the HA-tag was similarly cloned in 
front of the CTGF cDNA as in the Ad.TC-CTGF, however, cleavage was not as effective. 
The most probable reason for this finding is the difference in the tag length. The HA-tag 
seems to be cloned as a multicopy construct and thus cleavage by the signal peptide 
peptidase was not effective. In principle, the tagging of CTGF by TC is still an interesting 
strategy for real time tracking of CTGF in living cells, with assumedly minimal 
interference with the behavior of CTGF, due to the relatively small molecular weight of 
the tag, but the cloning strategy should be modified to overcome the problem of tag 
cleavage. Although the cloning of multiple TC tags at the N-terminus of CTGF gene 
sounds a good idea, the risk that this could influence the behavior of the CTGF protein 
becomes higher. In addition, the fact that the cleavage process of the tag is still 
occurring makes it impossible to distinguish between the endogenous and the cleaved 
TC-CTGF, which restricts the readout of certain experiments. Therefore, it is worthy to 
try to clone the TC tag within the first 130 amino acids, but verification steps would be 






Figure 34: Evaluation of the Ad.TC-CTGF in NRCF  
A) NRCF were incubated for 48 hr with Ad.EGFP (negative control adenovirus) or 
Ad.TC-CTGF, 10 µl of each virus stock was used per 1 ml medium. After that, the cells 
were fixed, permeabilized and incubated with a blocking solution. CTGF detected by IF 
staining (yellow) and the nuclei were stained with DAPI (blue). B) NRCF were incubated 
for 48 hr with Ad.EGFP, Ad.TC-CTGF or Ad.HA-CTGF (positive control). 10 µl of each 
virus stock was used per 1 ml medium. After that, the cells lysates and conditioned 
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Figure 32: The TC-CTGF fusion protein could be expressed in NRCF, but the
TC tag had been cleaved from CTGF, before it was secreted
A) NRCF were incubate overnight with Ad. EGFP (control adenovirus) or Ad. TC-
CTGF adenovirus. On the next day the cells were fixed, permeabilized and blocked.
CTGF was labeled yellow, and the nuclei were stained blue with DAPI . B) NRCF
were incubated overnight with Ad. EGFP, Ad. TC-CTGF or Ad.HA-CTGF (positive








A hallmark for heart failure is remodeling of the cardiac tissue, which is characterized by 
myocardial hypertrophy and fibrosis. Fibrosis occurs due to dysregulation of the 
extracellular matrix homeostasis. In the last few years, there was increasing interest in 
the contribution of the numerically predominant CF in this process, because these cells 
are largely responsible for the deposition and organization of the extracellular matrix 
components. In addition, these cells secrete a variety of growth factors and cytokines, 
which contribute to the progression of heart disease via autocrine and paracrine 
mechanisms. CTGF is one of the interesting proteins that are secreted by fibroblasts. 
The expression and secretion of this factor are upregulated not only in cardiac diseases, 
but also in almost all other fibrotic diseases occurring in various tissues. Moreover, 
several recent publications have reported increasing evidences for its direct role in the 
process of fibrosis. However, the mechanisms controlling the expression and secretion 
of CTGF in CF are still unclear. This work provides novel findings on the regulation of 
CTGF in CF by cytoskeleton-dependent and Ca2+-dependent signaling pathways. It 
provides thorough investigations on the Ca2+ handling in these cells, and discusses the 
role of actin filaments and microtubules on the status of the Golgi apparatus and the 
regulation of CTGF. It also pinpoints Ca2+ as a major regulator of the expression of 
CTGF with potential role for the actin and microtubules cytoskeleton in the underlying 
mechanism. Mechanistically, this work highlights PKC and calcineurin as major 
downstream targets for Ca2+ and shows potential crosstalk between their signaling 
pathways. At the same time, the Golgi apparatus and actin filaments were identified as 
targets for Ca2+, PKC and calcineurin, which creates a link between Ca2+-dependent and 
cytoskeleton-dependent signaling pathways.  
 
5.1. Regulation of the Ca2+ transient in CF 
 
Within this work, it could be shown that the Ang II-CaT involves the activation of the 
AT1R, Gq/11 proteins, PLC-β and IP3 receptors. This canonical Ca2+ release pathway 
has been already demonstrated to play a substantial role in the regulation of Ca2+ in 
diverse other cells like smooth muscle cells [81, 82]. However, in contrast to rat aortic 
smooth muscle cells [63] it was found by cholesterol depletion with CDX that this 
signaling cascade seems to reside at least partly in caveolae. Moreover, by inhibiting the 
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ER Ca2+ ATPase with TGN, and by analysing the effect of extracellular Ca2+ on the Ca2+ 
transient, it was found that the ER is probably the most important source of this ion. This 
is in line with a report by Brilla and coworkers, who demonstrated in adult rat CF that the 
Ang II-CaTs in the absence and presence of extracellular Ca2+ were comparable, 
therefore, they also suggested the intracellular Ca2+ stores to be the major source for the 
acute increase in the cytoplasmic Ca2+ levels in response to Ang II [173]. However, there 
is increasing evidence that the influx of Ca2+ from the extracellular space via diverse 
channels also plays a role in the Ca2+ homeostasis in CF. This includes a study from 
Chen and coworkers who demonstrated that at least on the mRNA level the expression 
of diverse channels including Ca(V)1.2, NCX3, PMCA1,3,4, TRPC1,3,4,6, STIM1, and 
Orai1-3 in human CF [174]. Ikeda and coworkers then confirmed the expression of the 
unselective Ca2+/Na+ TRPC1,3,4,6 channels in these cells. Furthermore, they showed 
that these channels and the reverse-mode of the Na+/Ca2+ exchanger influences the 
proliferative behavior of these cells [175]. This is in line with data presented by Harada 
and coworkers, who also showed that the specific TRPC3 inhibitor Pyr3 inhibited the 
proliferation of CF. As a mechanism, the authors analyzed the impact of Pyr3 on the 
regulation of Ca2+. They showed that the relatively slow, Ang II-induced Ca2+ influx in 
adult CF could be blocked by Pyr3 [176]. This type of Ang II-dependent, slow and 
persistent Ca2+ influx could not be detected within this work in a similar time frame. 
However, the incubation of neonatal CF with Pyr3 led to significant reduction of the basal 
cytoplasmic Ca2+ concentration. This discrepancy between data obtained in adult and 
neonatal CF might be explained by several reasons. First, it has been shown that the 
TRPC3 possesses a substantial constitutive activity, which could be of different height. 
Second, Schleifer and coworkers demonstrated recently that Pyr3 additionally inhibits 
the store-operated Ca2+ influx, which could be also differently involved [177]. Third, the 
already in smooth muscle cell described coupling between the TRPC3 and the IP3R 
[125-127] might play a so far unevaluated role in CF. Further studies are needed to 
address this issue. 
In addition to the decrease in the basal cytosolic Ca2+ concentration, Pyr3 substantially 
inhibited the oscillation of Ca2+ in CF in this work. Ca2+ oscillation is a repetitive cyclical 
change in the cytoplasmic Ca2+ concentration, which has been observed in different non-





5.2. Regulation of the Ca2+ oscillation in CF 
 
In summary, in this thesis it could be shown that the Ca2+ oscillation occurred in around 
one third of the cells independent of the passage number and could be increased by 
submaximal Ang II concentrations and inhibited by TGN and Pyr3, arguing for a role of 
intracellular Ca2+ stores but also for an influx of Ca2+ from the extracellular space. 
Although, so far only few data is available for CF on the oscillation of Ca2+, this finding is 
in line with data presented by Chen and coworkers, who reported that spontaneous Ca2+ 
oscillation occurred in 29% of primary human CF. With respect to the mechanism the 
authors discussed a role of the PLC-β/IP3R system and of L-type Ca2+ channels [174]. 
For other cell types, it has already been described that the TRPC3 channels can 
mediate agonist-activated Ca2+ oscillation via non-capacitative Ca2+ entry [117]. But also 
other mechanisms have been attributed to this process which has not been evaluated 
within this work, such as extracellular and intracellular mechanical stress [128]. 
Independent of the mechanism how Ca2+ oscillations are generated, the outcome of 
these cyclic changes is not clear. There is evidence that the amplitude, frequency and 
duration of these signals actually play a major role in the regulation of different cellular 
processes such as, proliferation, contraction and secretion [117, 118], and it was shown 
by several publications that it is involved in the efficiency and specificity of gene 
expression [178], but it was not possible to find a link between this process and the 
regulation of CTGF expression in NRCF. However, the inhibition of TRPC3 channels 
augmented the CTGF secretion in CF. Future experiments have to be performed to 
unravel the role of this long known phenomenon in CF.  
 
5.3. Influence of ROS-regulating mediators on the Ca2+ handing in CF 
 
Within this thesis, the role of the reactive oxygen species (ROS) producing NADPH 
oxidase in the regulation of the Ca2+ handling in CF was analyzed. By using the specific 
peptide gp91-ds-tat, which can penetrate the plasma membrane and inhibit the 
association of the essential p47phox with the transmembrane subunits of the NADPH 
oxidase NOX2, it could be demonstrated that the amplitude of the Ang II-CaT was 
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significantly reduced. Similar results were obtained by inhibiting the activation of the 
accessory activator Rac1 with NSC, which argues for a role of ROS in the regulation of 
Ca2+ in CF. With this respect, it has already been demonstrated by Colston and 
coworkers that a short exposure of CF to exogenously added H2O2 can induced a Ca
2+ 
transient without any other stimulus [179]. So far, however, it is not clear which 
mechanism is responsible for this regulation. On one hand, Colston and coworkers could 
partly block this transient by IP3R inhibition with XeC and TGN, but also by the depletion 
of extracellular Ca2+. These findings suggested that the ROS-induced increase in Ca2+ is 
not only dependent on intracellular Ca2+ stores, but also on the influx of Ca2+ from the 
extracellular space. On the other hand, Takahashi and coworkers postulated the 
involvement of the TRPM2 channel in the ROS-induced Ca2+ influx in CF. The TRPM2 is 
a non-selective Ca2+-permeable channel, which is upregulated in hypoxia and stimulated 
by ROS [180]. Finally, data presented by Fujii supported the idea of the Ca2+ influx as 
the main ROS target, because they showed that in CF in the absence of extracellular 
Ca2+ the Ang II-CaT could not be decreased by the expression of dominant negative 
variants of Rac1 and p47phox [67]. To finally understand the role of ROS in the handling 
of Ca2+ in CF further studies have to be performed. 
Besides the inhibitory effect of the gp91-ds-tat peptide and of the inhibitor of Rac1 
activation on the amplitude of the Ang II-CaT, distinct effects of both molecules on the 
Ca2+ loading in the mitochondria was observed. The uptake of Ca2+ in the mitochondria 
is a well-documented process, which occurs in most cells when the Ca2+ concentration 
rises above 1 µM [88, 181]. Depending on the increase of Ca2+ in the mitochondria the 
outcome is either an increase in ATP synthesis or in case of a Ca2+ overload the 
enhanced generation of ROS, triggering of the permeability transition pore, and 
cytochrome c release, leading to cell apoptosis. Recently, a new junction has been 
identified which allows the direct, spatially highly controlled flux of Ca2+ from the ER into 
the mitochondria. This region has been called mitochondria-associated ER membranes 
(MAM) or the ER-mitochondria-juxtaposition. It has been shown that within this junction 
several Ca2+ channels are clustered, including the IP3R in the ER membrane, the 
voltage-dependent anion channel in the outer mitochondrial membrane and the 
mitochondrial Ca2+ uniporter in the inner mitochondrial membrane. With respect to the 
Ca2+ efflux from the mitochondria, the Na+-Ca2+-exchanger 3 (NCX3) in the outer 
mitochondrial membrane was identified as a possible candidate [182]. Although, it is not 
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clear in this thesis how the observed decrease and increase in the duration of the rise in 
mitochondrial Ca2+ by gp91-ds-tat and NSC, respectively, takes place, there is 
increasing evidence data that most of the proteins involved in the mitochondrial Ca2+ flux 
are redox-sensitive [183]. In addition, it was shown that in endothelial cells glucose 
induces total and mitochondrial ROS, mitochondrial DNA damage and cell apoptosis, 
which could be blocked by NSC [184]. Moreover, Rac1 has been found at the membrane 
of mitochondria where it interacts with Bcl-2 and its functional inhibition or silencing 
decrease mitochondrial O2
.- levels and enhances apoptosis sensitivity [185]. However, 
these studies provided no links to a potential role of the mitochondrial Ca2+ regulation.  
In summary, the obtained data in this thesis and the recent literature suggest that ROS 
production is important for the cytosolic Ca2+ transient and for the regulation of the Ca2+ 
flux in mitochondria, however, the underlying mechanisms are still obscure. It has to be 
also taken into account that Rac1 is not only a functional part of some isoforms of the 
NADPH oxidases but also possess other downstream target like the p21-activated 
kinases.  
 
5.4. Mechanism of CTGF regulation by cytoskeleton-dependent and Ca2+-
dependent signaling pathways 
 
The mechanical properties of cells are strongly dependent on the organization and 
degree of actin filaments polymerization. LAT-A can inhibit the polymerization of these 
filaments mainly by binding to G-actin monomers in the cytosol [186]. Interestingly, the 
chelation or depletion of the intracellular Ca2+ by BAPTA-AM or TGN, respectively, 
disrupted actin filaments, which is in line with a recent publication by Kuwahara, who 
reported that the elevation of the intracellular Ca2+ concentration in mesothelial cells was 
associated with increased actin filaments polymerization and organization [187]. 
Moreover, it was shown by this thesis that the inhibition of PKC, the downstream target 
of Ca2+, was also associated with the disruption of actin filaments. Several working 
groups reported that PKC mediates the activation of RhoA-ROCK in different cell types 
including smooth muscle cells and endothelial cells [188, 189]. A mechanistic study by 
Dovas and coworkers in fibroblasts provided evidence that PKCα mediates the activation 
of RhoA by syndican 4, a transmembrane heparin sulphate proteoglycan that works with 
integrin in the formation of the focal adhesions. In addition, the study provided evidence 
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that syndican 4–PKCα–RhoA signaling pathway was necessary for the formation and 
maintenance of the actin stress fibers [190]. RhoA maintains the stability of actin 
filaments via ROCK-mediated LIM-kinase phosphorylation, which in turn phosphorylates 
and inhibits cofilin, the actin filaments depolymerizing protein [136]. RhoA in addition, 
activates diaphanous-related formins (mDia1 and mDia2), which nucleate the formation 
of actin filaments and prevent the binding of plus-end capping proteins, thus keeping the 
progress of actin filaments polymerization [191-194]. Within this thesis, the disruption of 
actin filaments was most of the times associated with the inhibition of CTGF expression 
and secretion. With this respect, it has already been demonstrated by Muehlich and 
coworkers that the level of CTGF expression in endothelial cells was proportionally 
related to the degree of actin filaments polymerization, which was dependent on RhoA 
activation, and mediated via SRF transcription factor [168]. The activation of SRF was 
shown to be inhibited consequently to actin filaments depolymerization and the elevation 
of G-actin monomers concentration that sequester MRTF, thus preventing it from 
complexing with SRF in the nucleus, as reviewed in section 2.7.4.   
In this project, the depolymerization of actin filaments, whether directly by LAT-A or 
indirectly via interference with Ca2+ signaling, was associated with the disruption of the 
Golgi apparatus and the inhibition of CTGF secretion. Consistent with these findings, 
Lazaro-Dieguez and coworkers reported that the disruption of actin filament changes the 
morphology and integrity of the Golgi apparatus [195], which was found by another 
group to inhibit protein transportation through the cisternae of the Golgi apparatus, 
resulting in the inhibition of the cellular secretion [196]. In addition, Chen and coworkers 
demonstrated that the localization of CTGF to the Golgi apparatus was essential for 
successful CTGF secretion [197]. In the same time as reviewed in section 2.6.1, Ca2+ 
has already been demonstrated to be involved in the trafficking of the secretory vesicles 
and in the fusion of the these vesicles with the target cell membrane during exocytosis. 
Moreover, several reports highlighted the role of Ca2+-dependent actin coating of 
secretory vesicles as an important factor for the efficient release of the content of 
secretory vesicles during exocytosis [198, 199]. Therefore, it can be postulated that the 
regulation of CTGF secretion involves actin-dependent and Ca2+-dependent 
mechanisms, with potential crosstalk between these two mechanisms, and involves 
functional Golgi apparatus. However, the inhibition of CTGF expression per se is also 
expected to contribute to the inhibition of secretion. 
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In the same context, the role of calcineurin in the regulation of CTGF was also 
investigated within this thesis. It was found that the inhibition of calcineurin by CsA 
significantly enhanced CTGF expression. This was associated with the loss of the cell 
membrane complexities and changes in the morphology of the Golgi apparatus, but 
without clear effects on the actin filaments and microtubules. Several reports have 
already highlighted a role for calcineurin in the dynamic regulation of the actin 
cytoskeleton. Zhang and coworkers demonstrated that calcineurin mediated the 
activation of cofilin [200]. A mechanistic study by Wang and coworkers using cell-free 
assays demonstrated that calcineurin dephosphorylated slingshot 1L protein 
phosphatase, which in turn dephosphorylated and activated cofilin [201]. Moreover, Li 
and coworkers recently reported that CsA could inhibit the dephosphorylation of cofilin, 
resulting in the stabilization of actin filaments [202]. This effect is speculated to enhance 
CTGF gene expression, as it would negatively influence the level of the monomeric-G 
actin and enhance SRF-induced gene expression as reviewed in section 2.7.4.  On the 
other hand, Akool and coworkers demonstrated in mesangial cells that the inhibition of 
calcineurin by CsA was associated with rapid activation of TGF-β/Smad signaling and 
increased DNA binding of Smad-2, -3 and -4 to the Smad-binding promoter element, 
resulting in the induction of expression of several genes including CTGF. 
Mechanistically, they suggested that CsA could induce ROS generation that activated 
latent TGF-β, which in turn induced gene expression via activation of Smad and p38 
MAPK signaling pathways [203]. In another approach, a proteomics study by Van 
Summeren and coworkers demonstrated that CsA induced endoplasmic reticulum (ER) 
stress in a cell culture of hepatocytes. The authors showed that CsA treatment was 
associated with the differential expression of several chaperone proteins, which are 
normally associated with the induction of ER stress and the disruption of the ER-Golgi 
transport [204]. Consistent with these findings, Cheng and coworkers showed that 
treatment of rat kidney epithelial cells with CsA was associated with the induction of ER 
stress response related proteins including ATF6 [205], which was shown by another 
group to be involved in the activation of SRF [206]. Therefore, it can be hypothesized 
that the induction of CTGF expression by CsA results, at least in part, from the ATF6-
induced ER-stress. Further experiments are required to test this hypothesis.  
The role of microtubules in the regulation of CTGF was also investigated within this 
thesis by using colchicine, which is a clinically used drug known to depolymerize 
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microtubules. The disruption of the microtubules by colchicine resulted in the 
fragmentation of the Golgi apparatus into CTGF-containing membranous structures, 
which were dispersed randomly throughout the cytosol. At the same time, CTGF 
expression and secretion were strongly induced and were uncoupled from the AT1R 
signaling cascade. The disruption of the Golgi apparatus subsequently to microtubule 
disruption is in line with previous findings by Miller and coworkers, who reported that the 
spatial organization of the Golgi apparatus is regulated by two subsets of microtubules: 
the radial centrosomal microtubule array that positions the Golgi apparatus in the center 
of the cell, and the Golgi-derived microtubules that draw the Golgi ministacks together to 
maintain the continuity and proper morphology of the Golgi apparatus complex [207]. 
The augmenting effect of colchicine on CTGF expression was reported previously in 
immortalized human renal fibroblasts by Ott and coworkers, who demonstrated that the 
induction of CTGF by colchicine was associated with the activation of RhoA, and that the 
pharmacological inhibition of RhoA-ROCK was associated with a reduction in colchicine-
induced CTGF expression [208]. In addition, Graness and coworkers demonstrated in 
the same cell type that the colchicine-induced CTGF expression was associated with the 
recruitment of patchy actin filaments to the cell cortex. This was associated with the 
reorganization of the focal contact into strong clusters, and with the activation of RhoA-
ROCK, focal adhesion kinase and Src-family kinases [170]. Consistent with these 
findings, several other reports provided evidences that colchicine treatment could alter 
the G-actin/filamentous actin ratio by inducing actin filaments polymerization and stress 
fiber formation, thus increasing the cellular rigidity [209-211].  
In summary, the obtained data in this thesis and the discussed literature suggest that 
both the cytoskeleton-dependent signaling pathway and the Ca2+-dependent signaling 
pathway influence the integrity and morphology of the Golgi apparatus, and play a 







5.4.1. Role of ROS in the regulation of CTGF  
 
The role of ROS in the regulation of CTGF was evaluated within this thesis by 
specifically targeting NOX2 isozyme by the inhibitory peptide gp91-ds-tat. Although 
treatment with gp91-ds-tat inhibited the ΔRFUMax of the Ang II-CaT, it did not influence 
the expression or secretion of CTGF. On the other hand, the inhibition of Rac1 activation 
by NSC significantly inhibited ΔRFUMax of the Ang II-CaT, and was shown to reduce the 
level of intracellular CTGF (personal communication). Rupérez and coworkers reported 
that H2O2 increased CTGF mRNA and protein expression independently of TGF-β [59]. 
Park and coworkers demonstrated that this effect could be mediated by Janus kinase 
(JAK)-2 and -3 signaling pathway [212]. In addition, Adam and coworkers showed that 
the inhibition of Rac1 activation by NSC significantly inhibited the induction effect of   
Ang II on the expression of CTGF in both NRCF and neonatal rat cardiomyocytes. The 
authors suggested that the underlying mechanism could involve the generation of ROS 
[213]. However, Rac1 is a cofactor not only of NOX2 complex but also of NOX1 and 
NOX3 complexes [214], suggesting that the potential regulation of CTGF by ROS could 
involve NOX1 and NOX3 isozymes. Therefore, targeted studies on NOX1 and NOX3 are 
required to unravel the potential role of ROS in the regulation of CTGF. 
 
5.4.2. Ca2+ is involved in the regulation of CTGF in human cardiac fibroblasts 
 
Preliminary data obtained from experiments in normal human ventricular cardiac 
fibroblasts (NHCF-V) showed that Ca2+ and PKC were involved in the regulation of 
CTGF, which is in line with the findings in NRCF. In addition, these preliminary data 
showed that Rac1 is also involved in CTGF regulation, which is consistent with previous 
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